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A lthough FSHD is considered one of the most common inherited 
neuromuscular diseases, there is no 
specific therapeutic practice for it. So 
what can we do about it? First, we have 
to understand the mechanisms of the 
disease and to identify the crucial links 
in the chain of molecular reactions 
that underline FSHD. Furthermore, 
we have to develop a system to screen 
various therapeutic approaches, and in 
the end to generate an animal model 
where clinical relevance of therapy 
can be determined. When I joined the 
FSHD group lead by Dr. Michael Kyba 
at University of Texas Southwestern six 
years ago to develop a specific therapy 
for FSHD all of the above was considered 
to be a big enigma. We started working 
with DUX41, the gene within D4Z4, due 
to the similarity of its homeodomains 
to those of the master myogenic genes 
Pax3 and Pax72. We postulated that both 
genes compete for the same target DNA 
sequences and with that the function of 
myogenic cells is impaired. At that time 
only a small portion of the scientific 
community, led by Alexandra Belayew 
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Two exciting papers were recently pub-lished on possible approaches for treat-
ing FSHD using a disease gene silencing 
approach called RNA interference (RNAi). 
The details emerged within one month 
of each other in the journal Molecular 
Therapy. The two complementary stud-
ies were performed by different teams of 
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scientists: the Harper Lab at The Ohio State 
University and Nationwide Children’s Hos-
pital in Columbus, Ohio, with a collabo-
rator in Modena, Italy; and the Gabellini 
and Chamberlain labs in Milan, Italy, and 
Seattle, Washington, respectively.
 RNA interference is a natural cellular 
process that controls the levels at which 
certain genes are expressed. In this sense, it 
operates less like an on/off switch and more 
like a molecular volume control knob. 
Over the last several years, many scientists 
have been working to co-opt these natural 
gene-silencing strategies for therapeutic 
purposes. Indeed, the main triggers of 
RNAi in the cell, called inhibitory RNAs or 
microRNAs, can be rationally designed in 
the lab to knock down disease genes. In the 
two molecular therapy studies, the research 
teams rationally engineered FRG1-targeted 
inhibitory RNAs and then delivered them 
to muscles of dystrophic FRG1(-high) mice 
using adeno-associated viral (AAV) vectors, 
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Dr. Davide Gabellini with fellow researchers at the 2010 FSH Society FSHD research workshop
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T his issue of the FSH Watch reports great advances and dedicated people making remarkable progress to-
ward understanding and treating FSHD.  We are proud 
of the work detailed in this issue, moving us closer to 
understanding and treating FSHD.  The FSH Society has 
made excellent progress in bringing scientists into the 
field, allowing them to train, and in giving them oppor-
tunities to develop ideas in FSHD.  We hope you agree.
 In last year’s research issue we highlighted Society 
seed-funded work by Drs. Lemmers et al. in their paper 
“A Unifying Genetic Model for Facioscapulohumeral 
Muscular Dystrophy,” Science, August 19, 2010, that put 
forth a unified and long-sought explanation of the exact 
biological workings of a disease that affects an esti-
mated one in 14,000 or 22,100 Americans and 490,000 
individuals worldwide. Subsequently the Society an-
nounced that it  helped to fund a second critical advance 
in determining the cause of FSHD in PLoS Genetics, 
“Facioscapulohumeral Dystrophy: Incomplete Suppres-
sion of a Retrotransposed Gene,” on October 28, 2010, 
that shows that the disease is caused by the inefficient 
suppression of a DUX4 gene that is normally expressed 
only in early development. 
 The FSH Society’s approach to solving FSHD is 
pragmatic. We are now studying the “FSHD causing 
targets” in our translational research phase to enable us 
to initiate therapeutic clinical trials.  In this issue, we 
highlight efforts in each of the areas supported by the 
Society – mechanistic, translational, pre-clinical and 
clinical. The FSH Society continues to fund ground 
breaking and early-stage efforts in research, translational 
research, small molecule screening and clinical efforts. 
As you read about the projects we’ve recently funded 
and the updates from scientists all over the world, please 
remember that great things are happening, and they 
are only made possible by your financial donations and 
willingness to actively participate in research efforts. 
Please consider participating in 
studies highlighted in this issue, 
including the natural history 
study and developing biomark-
ers for FSHD.
 The FSH Society’s research 
portfolio seeks a good balance 
between conservative and in-
novative approaches in devel-
oping our knowledge of how 
FSHD works. We are constantly 
readjusting between following 
the “published paradigm” to 
guide FSHD progress with that of setting out in new 
innovative directions to improve our understanding 
of the disease. Both attitudes are appropriate. In times 
like these, when the research community struggles with 
developing a high-confidence therapeutic target, a bias 
towards innovation is appropriate.
 A top priority as outlined by the international com-
munity during the most recent Society research planning 
workshop is to independently verify and confirm the 
DUX4 hypothesis as published in Science in 2010. And if 
confirmed, move to understand normal DUX4 function, 
and finally, move towards understanding the naturally 
occurring variability of DUX4 to allow scientists to 
manipulate the disease in our favor. Currently, the pub-
lished paradigm is that DUX4 is necessary and sufficient 
to cause FSHD. However, if it turns out that DUX4 is 
necessary but not sufficient or even not necessary to 
cause FSHD, then the choices of a target and pathway 
are markedly different. It is one thing to eliminate a pro-
tein that you are not supposed to have at all in muscle 
and another to modulate a protein that has a resolution 
near the noise floor of detection and may be expressed 
at different thresholds in individuals with FSHD and 
without FSHD.  
Daniel Paul Perez
President & CEO
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 Two papers on possible approaches for treating FSHD using 
RNA interference (RNAi therapy) were recently published by the 
Harper Lab at The Ohio State University and Nationwide Chil-
dren’s Hospital in Columbus, Ohio, with a collaborator in Modena, 
Italy; and the Gabellini and Chamberlain labs in Milan, Italy, and 
Seattle, Washington, respectively in Molecular Therapy. The two 
complementary studies are the first successful proof of concept of a 
possible therapeutic approach for FSHD.  Using a well known and 
published mouse model of FSHD, with an over expression of a pos-
sible candidate gene for FSHD the FRG1 gene, scientists used RNA 
interference to silence the unwanted by products of a gene associat-
ed with FSHD. Both groups acknowledged the strengths and weak-
ness of FRG1 as the target gene for FSHD, the prospect of DUX4 
being the target for FSHD, and the ease of changing the gene of 
choice to knock-down using this technique. The caveat being that, 
the up regulated FRG1 transcript hasn’t been consistently found 
in humans with FSHD while the mouse FRG1 mouse model has a 
myopathic phenotype that is visibly reversed when it is knocked 
down. While the opposite is with DUX4 -- the DUX4 transcript is 
accessible in human FSHD tissues though it has been very difficult 
to create a viable DUX4 mouse, and additionally, a DUX4 mouse 
with a visible phenotype that can be tested using RNAi. 
 Patents are now being filed for various techniques of modifying 
gene and protein expression in FSHD.  Large pharmaceutical and bio-
technology companies are scrutinizing DUX4 as a target for FSHD.  
But the necessity remains to verify the DUX4 results presented in 
2010 with a large number of FSHD samples. You can help here by 
donating blood, skin and muscle tissue to research centers needing 
human FSHD-biomaterials.  The Society is trying to  provide the 
reagents, findings and animal models used in the translational and 
pre-clinical research process.  The Society has funded the creation of 
more than two-dozen transgenic animal models and we continue to 
push forward.  We consistently ask our grantees to publish on these 
models (not always easy to do) and to distribute and collaborate on 
these models. We are hopeful that the large scale funding agencies 
will deem it acceptable for them to verify and vet out this DUX4 
finding through translational and clinical trials efforts that are well 
established for other dystrophies.
 We remain deeply concerned that FSHD research efforts are not 
functioning at the proper levels of funding and running on a re-
duced economy as compared to peer-diseases and diseases of similar 
economic burden. We have made this evident in our Congressional 
testimony and report language.  We are also working side-by-side and 
in contact with other FSHD-agencies worldwide (U.S. NIH, MDA 
USA, AFM France, Stichting FSHD Holland, FSHD Global Australia, 
Pacific Northwest Friends, Muscular Dystrophy Canada, Coopera-
tive International Neuromuscular Research Group, Treat-NMD) to 
address resources and funding needed. We all need to amicably and 
collectively contribute to solve FSHD.
 As we move forward into translational areas, it is absolutely nec-
essary to verify the mechanism and target. We can then move forward 
with confidence with therapeutic trials. Not doing so  might dilute 
efforts to achieve such especially in these tough economic times for 
research funding. The Society continues to educate and advocate 
for more funding from large funding agencies and the U.S. federal 
government. We will need your help in reaching out to members 
of Congress to let them know how FSHD affects you, that a well 
funded NIH is necessary, and that not only will cuts in spending slow 
things down for FSHD research progress but increases in revenue are 
needed in FSHD at this critical time.
 Since our last issue of the FSH Watch, we have lost good friends 
and family members to the ravages of FSHD. I dedicate this issue to 
Mr. Edward M. Schechter, who passed away on July 2. Ed was a con-
stant champion for everyday folks suffering and living with FSHD. Ed 
made the FSH Society’s longstanding achievements in FSHD possible 
through his guidance and the funding of the Marjorie Bronfman post-
doctoral fellowships. We cannot deny the terribly destructive and 
debilitating aspects of FSHD. Your support is vitally needed. Thank 
you again for your continued support of the FSH Society and our 
work. Please consider giving as generously as you can to enable us to 
continue the Society’s educational and advocacy efforts and amazing 
progress made in research.
— Daniel Paul Perez
President & CEO
FSH Watch
Beth Johnston joins the fsh society Board of directors t
Beth joined the Board of Directors in 2011. A native of Colorado, she received a Master of Business 
Administration from University of Denver and a Bachelor of Science, Business Management & Finance 
from Colorado State University. She has worked in information technology, project management, high-
technology consulting, telecommunications and real estate. Beth volunteers for several organizations 
in New York where she now lives; she currently serves as Vice President of the St. Augustine Home & 
School Board in Ossining New York and will become President for the  2011-2012 school year. Beth is 
co-chair of the annual FSH Society fundraiser, “A Festive Evening of Song.”  Beth’s interest in the FSH 
Society stems directly from the fundraising efforts she has been overseeing during the last five years. 
Second only to supporting efforts to raise the critical funds necessary for FSHD research, she feels 
that raising awareness of both the disease itself and the function of the FSH Society are the vital areas 
where she can contribute. Beth serves as a director and on the development committee. Beth and her 
husband Jeff have two daughters, Nicole and Samantha.
Beth Johnston with her husband Jeff Johnston at  
the 2011 New York Festive Evening of Song
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Rationale for natural history studies of FSHD   
Ground work and preparations for clinical trials in FSHD
by Jean K. Mah, M.d., M.sc., FRCPC
On behalf of the Cooperative International Neuromuscular Research Group 
Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada
     C l i n i C a l 
Despite recent breakthroughs in under-standing the molecular genetics of FSHD, 
the exact mechanism(s) responsible for the 
variability of the disease remain undefined, 
and there is currently no cure for FSHD. 
Emerging therapeutic trials will benefit from 
the availability of natural history data and 
reliable outcome measures for both children 
and adults with FSHD. 
 The study of natural history in medicine 
refers to a careful and systematic descriptive 
study of the uninterrupted progression of 
a disease that occurs in affected individu-
als over time, starting from the beginning 
(infancy or early childhood) and extending 
throughout the course of the illness (adoles-
cence, adulthood) until the end (menopause, 
senescence). A thorough knowledge of the 
natural history of disease is important for de-
veloping effective strategies towards disease 
prevention and treatment. It also provides 
essential information regarding potential bio-
markers to disease expression and contrib-
utes to the development of a future clinical 
trials network. 
 In the case of FSHD, many individuals 
are generally healthy until adolescence or 
young adulthood when the onset of facial or 
shoulder weakness subsequently brings them 
to medical attention. Recognition of this 
preclinical phase of the disease is important 
as it provides a window of opportunity for 
potential disease modification. For example, 
genetically engineered strategies that are 
designed to halt the progression of FSHD 
can potentially keep these young individu-
als symptom-free for the rest of their lives. 
As well, if the rate or degree of change in the 
strength of individual or groups of muscles 
among untreated individuals with FSHD 
over a defined period of time is known, the 
information can then be used as one of the 
outcome measures to test the effectiveness 
of new treatments for FSHD. Changes that 
can be easily (and consistently) detected in 
the majority of cases are especially valu-
able as they require less number of study 
participants (i.e. smaller sample size) and 
the clinical trials can be completed within a 
shorter period of time (thus reducing cost 
and effort). Furthermore, an awareness of the 
differences in the rate of progression of dis-
ease among individuals with similar genetic 
mutations may lead to the identification of 
environmental factors or other genetic modi-
fiers of FSHD. 
 Your on-going support and participation 
will make it possible for us to understand the 
natural history of FSHD. Thank you for your 
consideration of our work. FSH Watch
in memory of edward m. schechter 1920 – 2011 t
Edward Schechter of Shavertown, Pennsylvania, died on July 2, 2011, 
at age 91 at his home with many members of his loving family at his 
side. He fought a long and courageous battle for more than forty years 
against FSHD.
 Born in New York City in 1920, Ed was the son of Jacob and Meta 
Schechter. He grew up in New York and graduated from DeWitt Clinton 
High School and Dartmouth College. He attended Harvard Business 
School for two years, leaving shortly before graduation in 1942 to enlist in 
U.S. Army and fight in World War II. He was trained as an infantry officer 
with the 10th Mountain Division in Colorado and Washington, but he was 
deployed to the Pacific Theater where he served as an intelligence officer 
in battles throughout the islands of the South Pacific. He was among the 
first American soldiers to enter Hiroshima following the dropping of the 
atomic bomb. After seeing the devastation and suffering there, he turned 
in his weapons and led the rest of his life as a pacifist. Ed attained the 
rank of Captain and earned the Silver and Bronze Stars. Ed married Betty 
Jane Goodstein in 1944. Theirs was a long and loving marriage, and they 
celebrated their 67th wedding anniversary in January 2011.
 Ed was truly a champion of FSHD research and many other just 
causes. He cared deeply about the FSH Society, patients and their fami-
lies. He was a mentor, a great friend, a deep intellect, and an extraordi-
narily ethical and just man. We will miss his stunningly clear and boom-
ing voice, his direction, motivation and imperative to get things done in 
FSHD. It was a true reflection of Ed’s character, courage, kindness and 
strength that he made telephone calls in his last days to say goodbye to 
people and causes he cared deeply about. The FSH Society’s successes 
in FSHD research to date are greatly owed to the support of Ed and his 
family. We will miss him constantly, and we regret we could not do more 
to alleviate FSHD during his lifetime.
 The FSH Society is deeply indebted to Edward Schechter, brother of 
Mrs. Bronfman, of the Marjorie and Gerald Bronfman Foundation, and 
other members of their families for the advances that have been made 
possible in FSHD research worldwide. Edward Schechter deserves 
much gratitude for his stewardship of the Marjorie Bronfman grants to 
the FSH Society and their ensuing research breakthroughs. 
 This issue of the FSH Watch is dedicated to the memory of Ed 
Schechter, a rare gentleman and a true friend to the FSH Society, many 
of its members and his fellow FSHD patients.
At the wishes of Ed’s family and friends, the FSH Society will establish an 
endowment fund to be called the “Ed Schechter Fund for FSHD,” to recog-
nize his many years of care and concern not only for the FSH Society and 
FSHD research, but also his keen interest in the individuals carrying out 
this research. When you make your membership gift at this time, please 
join with others in remembering Edward Schechter and make a gift to the 
FSH Society’s Schechter Fund for FSHD to help support research.
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International FSH consortium outlines research priorities for FSHD 
Identifying priorities to solve FSHD
by Fsh sOCiety
Watertown, Massachusetts
scientists, patients, advocates, biotech and pharmaceutical com-panies, and clinicians from throughout the world gathered at 
Boston Biomedical Research Institute (BBRI) late October 2010 for 
the Research Planning Meeting for FSHD. 
 The meeting focused on collaborating to find new treatments 
and cures for FSHD. Meeting scientific clinical and research co-
chairs were: Rabi Tawil, M.D., University of Rochester Medical 
Center & Fields Center for FSHD and Neuromuscular Research; 
and, Silvère van der Maarel, Ph.D., Leiden University Medical 
Center & Fields Center for FSHD and Neuromuscular Research. 
Daniel Paul Perez, President and co-founder of the FSH Society, 
co-organized the meeting. Professor David Housman, Chairman of 
the FSH Society Scientific Advisory Board (SAB) and many mem-
bers of the Society’s SAB were present and helped moderate the 
meeting. The meeting was co-hosted by Dr. Charles P. Emerson, 
Jr., distinguished scientist and Director of the BBRI, and Co-Di-
rector, along with FSH Society Board and SAB member Dr. Louis 
Kunkel of Harvard Medical School and Children’s Hospital of the 
NIH Eunice Shriver Kennedy NICHD Sen. Paul D. Wellstone MD 
CRC for FSHD. Also joining the meetings was Ljubisa Vitkovic, 
Ph.D., program director for muscular dystrophy at the NICHD.
 Sponsors for the event included Association Française Contre 
les Myopathies (AFM), The Fields Center for FSHD and Neuro-
muscular Research, FSH Society, FSHD Global Research Founda-
tion, NIH Eunice Kennedy Shriver NICHD Boston Biomedical 
Research Institute Senator Paul D. Wellstone MDCRC, and the 
Muscular Dystrophy Association United States (MDAUSA).
 The group recommended that, given the recent develop-
ments in the definition of the molecular mechanism of FSHD, 
the potential exists that within one or two years, evidence-based 
intervention strategies, therapeutics, and clinical trials could be 
planned and conducted. Hence, immediate priorities should be to 
independently-verify and confirm the DUX4 hypothesis as pub-
lished in Science in 2010, and if this hypothesis is confirmed then 
understand normal DUX4 function, and finally, move towards 
understanding the naturally occurring variability of DUX4 to al-
low scientists to manipulate the disease therapeutically. The group 
stated that the FSHD research community needs to be prepared 
for this new era, by accelerating efforts in the following ten areas:
1. Shareable Protocols. There is a need for access to FSHD re-
search protocols and experimental methods by FSHD research-
ers internationally. Readily available, clear and well defined 
research protocols are needed to allow verification, standard-
ization and corroboration of research findings and publica-
tions. 
2. Common and shareable materials and data by the entire community. 
There is a need for global and international biomaterials and 
data management. Schemas are needed to identify source and 
context of biomaterials and data, meaningful data identifiers, 
and easily accessible bio-repositories and data sources.
3. Corroborate and verify DUX4 finding. This line of work will 
be instrumental to pinpoint the real identity of FSHD1A 
(chromosome-4-D4Z4-contraction-linked cases) and FSHD1B 
(chromosome-4-non-D4Z4-contraction-linked cases & non-chro-
mosome-4-linked cases). This information will form the basis for 
evidence-based intervention. There is a need to verify and repro-
duce the DUX4 finding using multiple sites and patient materials.
4.  FSHD alleles in the context of population genetics need to be de-
fined. There is a need to understand the normal function of the 
short DUX4 transcript in every human being and the abnormal 
function of toxic long-form of the DUX4 transcript.
5.  Biomarkers. There is obvious need for monitoring interven-
tion. There is the need to define biomarkers for clinical trials 
endpoints, to understand the FSHD at multiple omics levels 
{proteomics, genomics, transcriptomics, metabolomics) and to 
understand pathways and signaling of FSHD through “omics” 
analysis.
6.  FSHD clinical evaluation scales/systems need be defined under 
a single agreed standard. There is an important need to have a 
comprehensive and single clinical evaluation standard to allow a 
list of clinical identifiers and parameters to be assembled into a 
thorough and robust dataset. This can be applied to subsequent 
systems biology and –omics areas.
7.  Working groups/Mouse model working group consortium. There 
is a need for models and methods to interpret the current 
mechanistic paradigm of FSHD and fidelity of current data. An 
assessment of various modeling approaches is needed in order 
to achieve a consensus on the limits and capabilities of current 
modeling approaches.
8.  Model systems for mechanistic, intervention work and advance-
ment to clinical trials. We need to be able to understand the 
limits of both the data and the models. There is the need to 
address the complexity of FSHD in the context of mammalian 
A pair of distinguished FSHD scientists provide a stimulating overview of a research area 
at one of eight topical working sessions at the 2010 FSH Society FSHD planning meeting
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The importance of having a well-funded U.S. National Institutes of Health  
Report language to encourage NIH FSHD research efforts
by daniel PaUl PeReZ
FSH Society, Watertown, Massachusetts
     a d V O C a C y  &  e d U C a t O n
In May 2011, a letter was sent on be-half of individuals and families with 
FSHD led by Representatives Sam Farr 
(CA), Edward Markey (MA) and John 
Tierney (MA) to the Chairman and 
Ranking Member Appropriations Sub-
committee on Labor, HHS, Education 
asking the committee to add report 
language to the budget. We deeply 
appreciate the efforts of Congress-
men Farr, Markey and Tierney on this 
critical issue. Their letter asked the 
committee to “recall, that during the 
subcommittee’s April 7, 2011 hearing 
there was testimony about FSHD.  It 
is a form of muscular dystrophy, the 
most common form, in fact. With the 
passage of the Muscular Dystrophy 
Community Assistance, Research and 
Education (MD-CARE) Amendments 
of 2001 National Institutes of Health 
(NIH) funding for muscular dystrophy 
research quadrupled - from $21 mil-
lion in 2001 to $86 million in 2010. 
Of this amount, FSHD gets around 
$7 million for research. Duchenne 
Muscular Dystrophy (DMD) gets more 
than $44 million even though FSHD is the more prevalent form 
of MD.  In 2010, there were several studies that were published 
in recognized medical journals showing significant advances in 
research into understanding the origins of FSHD. To build on this 
new information FSHD advocates believe the mix of NIH funding 
that goes to the different kinds of MD needs to shift. Specifically, 
FSHD advocates believe FSHD research deserves more atten-
tion than it’s been getting especially now that there’s been break-
throughs. To emphasize the importance of these breakthroughs we 
suggest the committee add report language - like that below - that 
encourages NIH to expand and enhance its FSHD research.
The Committee is pleased to learn of research breakthroughs 
achieved last year in testing for causes of and research in FSHD. 
The Committee hopes such advances will be utilized as quickly 
as medically possible to develop possible treatments for FSHD. 
The Committee asks the Director of NIH to report back to the 
Committee within six months the actions NIH will take to ad-
dress FSHD research.
 Thank you for your attention to this important matter.” The 
FSH Society continues to advocate for an increase in NIH fund-
ing which in turn helps muscular dystrophy funding. As of this 
writing, the Congress is on recess and no Labor, HHS, Education 
appropriations bill and report has been put forth. One scenario 
that is concerning, is that, the Labor, HHS, Education appropria-
tions and report language will fall to the newly formed super-
committee and Congress will not accept the recommendation of 
the committee. The process would then default to a continuing 
resolution with last year’s budget and the “automatic trigger” 
in the debt ceiling reduction legislation will result in across the 
board cuts which would impact the NIH funding and its ability to 
fund research.  Cuts in NIH funding will have a significant impact 
on the economy and biomedical research. The following links are 
to the Senate Appropriation Subcommittee webpage that contains 
written testimony from Dr. Francis Collins, the overall Director of 
the NIH. In each you will find that he references economic data 
pertaining to NIH research funding. This data is linked (via foot-
note) to the reports that detail the extent of economic benefit and 
job creation. FY2012 Budget Hearing: http://appropriations.senate.
gov/ht-labor.cfm?method=hearings.view&id=8a1dcace-6f68-4e35-
ad94-4409966e2ffb (starting on page 2).  FY2011 Budget Hearing: 
http://appropriations.senate.gov/ht-labor.cfm?method=hearings.
view&id=ccfabaa6-bbfe-46fa-8cf8-5925a7f89a1c (starting on 
page 11).
 The FSH Society encourages each of us affected by FSHD to 
communicate with your Senator or two Representatives your ex-
periences with FSHD and the importance of funding research on 
FSHD via a well funded NIH. Every voice counts! FSH Watch
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FSHD advocacy efforts on the U.S. President’s  
Muscular Dystrophy Coordinating Committee  
Ninth Annual Meeting highlights FSHD and translational research efforts
by daniel PaUl PeReZ
FSH Society, Watertown, Massachusetts
     a d V O C a C y  &  e d U C a t O n
In the previous edition of the FSH Watch we highlighted the FSH Society’s role and history in the MD-CARE Act and Daniel Paul Perez’s role on the federal advisory committee mandated in the 
Act the Muscular Dystrophy Coordinating Committee (MDCC).
 The FSH Society was instrumental in rewriting the MD CARE ACT 2001 to meet the needs 
of the entire community – people with all nine major types of muscular dystrophy - not just one 
type of muscular dystrophy. On December 18, 2001, Congress passed the Muscular Dystrophy 
Community Assistance Research and Education Act (MD CARE ACT), an unprecedented law 
mandating research, study and education on each type of muscular dystrophy. The law estab-
lished the Muscular Dystrophy Coordinating Committee (MDCC) oversight committee to coordi-
nate activities across the NIH, national research institutes and federal health programs relating to 
all forms of muscular dystrophy. In 2006, the MD-CARE Act expired. The entire muscular dys-
trophy community worked in support of re-authorization and Congress agreed it was important 
to continue the work in dystrophy. In 2008, the MD-CARE Act was re-authorized.
 The FSH Society made suggestions and comments to strengthen the Act for all muscular 
dystrophies. Since passage of the MD-CARE Act, nearly an additional $500 million has been 
funded by the NIH for muscular dystrophy research and education programs. The next time the 
MD CARE Act will need to be reauthorized is in 2013. Please contact the FSH Society if you are 
interested in helping with this effort.
 The MDCC is responsible for developing and implementing a plan for conducting and sup-
porting research and education on muscular dystrophy, measuring progress, and periodically 
reviewing and revising the plan. The U.S. Action Plan for the Muscular Dystrophies was com-
pleted and submitted to Congress in 2005. The plan will be revisited, re-assessed and revised 
in late-2011. To read the current U.S. Action Plan go to www.fshsociety.org click on Research tab 
at top, then click on FSHD Research Plans/U.S. NIH Action Plan in left hand navigation or see 
http://www.fshsociety.org/pages/resPNIHAction.html
 On April 20, 2011, the Ninth Annual Meeting of the Muscular Dystrophy Coordinating 
Committee was held in Rockville, Maryland. The meeting highlighted recent breakthroughs in 
understanding of the FSHD mechanism and efforts in translational research and preclinical re-
search to translate findings into therapies. The meeting began with introductions from Dr. Story 
Landis, MDCC Chair, NIH NINDS and Dr. John Porter, MDCC Executive Secretary, NIH NINDS. 
Introductions were followed by the NIH Overall Activities and Funding Report ARRA  Funding 
for Muscular Dystrophy by Dr. John Porter, NIH NINDS and an update on the Paul D. Wellstone 
Muscular Dystrophy Cooperative Research Centers Network by Dr. Glen Nuckolls, NIAMS.  
 Several informative presentations were given by the U.S. NIH and other federal agencies 
that included: “NIH Therapy Development Resources to Leverage for Muscular Dystrophy” 
by John McKew, of the newly formed NIH Center for Translational Therapeutics (NCTT); 
“Changes in the Rare Disease Landscape at the Food and Drug Administration (FDA) and NIH 
and Impact for Muscular Dystrophy” by Anne Pariser, FDA and Steve Groft, NIH Office of Rare 
Disease Research (ORDR); “New Federal Policies and Initiatives Impacting Muscular Dystrophy 
(Federal hESC policy update; FDA-NIH Joint Leadership Council; Other)” by Story Landis, 
NINDS; and “Challenges of Clinical Trials in Muscular Dystrophy [DMD]—Triaging Candidate 
Opportunities, Trial Recruitment, and Communication of Trial Rationale and Results” by Kurt 
Fischbeck, NINDS, Berch Griggs, University of Rochester, and Pat Furlong, Parent Project 
Muscular Dystrophy.
 Most significantly, Dr. Stephen Tapscott, Fred Hutchinson Cancer Research Center, 
Seattle, Washington updated the committee on the recent breakthroughs in 2010  at his 
laboratory in understanding the FSHD mechanism in a talk titled: “Research Update: Build-
ing upon a Mechanistic Breakthrough—Lessons Learned for the Muscular Dystrophies.”  
Other reports from non-NIH federal agencies included a talk given by: Dr. Mark Swanson, 
. . . continued on page 26
MArJOriE BrONFMAN FSHD 
rESEArCH GrANt FOr 2011  
The generosity and commitment of 
Marjorie Bronfman to FshD research 
began in 1997 when she began to make 
research grants to the Fsh society. Mrs. 
Bronfman has renewed her commitment 
each year, including in 2011 with a new 
grant of $50,000. Mrs. Bronfman, along 
with her late brother and one of her 
daughters, is affected with FshD.
 
Through a process of review and 
recommendation by the society’s 
scientific Advisory Board, grants 
are awarded for research fellowships 
(us$30,000-us$35,000/year) 
for research projects that show 
extraordinary promise to find the cause 
of FshD. The 2011 contribution and the 
many grants that have preceded it have 
generated significant progress in FshD 
research. 
The Fsh society is deeply indebted to 
Mrs. Bronfman, to the Marjorie and 
Gerald Bronfman Foundation, and other 
members of her family for the advances 
that have been made possible worldwide 
over these years and for the opportunity 
to continue advances in 2010. edward 
schechter, brother of Mrs. Bronfman, 
deserves much gratitude for these 
research grants and for the research 
breakthrough. For more information 
about research fellowships, please 
contact Daniel Paul Perez, President & 
ceO of the Fsh society, at daniel.perez@
fshsociety.org or call 781-275-7781 or 
617-658-7811.
2011 NEW YOrk FEStivAl OF 
SONG FEllOWSHiP GrANtS
The Fsh society New York Music 
and song Fellowship program was 
established in 2009 to help FshD 
research efforts. The Fsh society is 
indebted to board members, Judith 
seslowe of White Plains, New York, to 
Beth Johnston of Ossining, New York, 
and to their families and friends, for 
this groundbreaking effort on behalf of 
the FshD community. As FshD research 
moves ahead with new challenges, 
these awards have the potential to yield 
tremendous insights in FshD treatment. 
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which are benign in humans. FSHD Re-
gion Gene 1, otherwise known as FRG1, 
is a gene that is very near the deleted re-
gion of DNA associated with FSHD called 
the D4Z4 region and it has been widely 
studied as a possible candidate gene for 
FSHD.
 The first of these studies, published by 
Wallace, et al., on July 5, 2011, reported 
that AAV-delivered artificial microRNAs 
reduced toxic FRG1 levels and improved 
histological and functional muscle abnor-
malities associated with FRG1 over expres-
sion in mice. Drs. Wallace and Harper 
write that since this disease allele-specific 
gene silencing using RNAi is feasible, this 
“work supports that RNAi-based gene 
therapy is a promising candidate strategy 
for treating dominant myopathies, regard-
less of the causal genetic mutation.”  The 
Harper Lab is currently modifying this 
strategy to target another FSHD candidate gene, DUX4, as well as 
genes involved in other dominant muscular dystrophies, including 
some forms of Limb Girdle Muscular Dystrophy (LGMD).
 In the second study, published on August 9, 2011, Bortolanza, 
et al., note that administering shRNA, “with a single, systemic 
delivery they reached all the skeletal muscles body-wide and 
obtained a specific and long term FRG1 silencing. This was as-
sociated to a significant rescue of the phenotype at histological, 
molecular and functional levels. Importantly, there was no sign 
of toxicity. More importantly, they treated adult animals that had 
already developed signs of muscular dystrophy to closely mimic 
possible future clinical settings.  While in the paper we targeted 
the FRG1 gene, the same approach is easily applicable to DUX4 
knockdown by simply exchanging the shRNA expression cassette. 
Hence our approach is applicable to any FSHD candidate gene.”
 Both papers, authored by FSH Society funded researchers, are 
important for several reasons. First, they are the first successful 
proof of concept of a possible therapeutic approach for FSHD. 
Second, the approach is relevant for dominant myopathies in 
general. Mutations in at least 29 genes are responsible for a variety 
of genetically dominant muscle diseases. Considered as a group, 
these may affect as many as 1 individual in 2,400, making them 
the most common muscle disorders. Indeed, of the three most 
important muscle diseases (FSHD, Myotonic and Duchenne), 
FSHD and myotonic are genetically dominant disorders. Neverthe-
less, dominant myopathies have been largely neglected as targets 
of translational research because feasible molecular approaches for 
suppressing disease genes were unavailable until RNAi emerged 
a few years ago.  Based on their results, these researchers predict 
that approaches similar to the one that they described could be ap-
plicable (with modifications depending on the specific disease) to 
a large number of patients affected by dominant myopathies. The 
financial and other support of the FSH Society was very important 
in obtaining the results described in these papers. 
Drs. Gabellini, Harper, Wallace, Garwick-
Coppens and Tupler are all past or current 
FSH Society fellows. Drs. Gabellini, Harper 
and Wallace began their careers in FSHD 
with grants from the FSH Society. While we 
remain cautiously optimistic about a treat-
ment for FSHD, as the verification, corrobo-
ration and identification of the FSHD target 
(gene, RNA, protein) continues, this work is 
a major step forward in proof of concept of 
RNAi therapy in FSHD models. This work 
was made possible by a culmination over 
the years of a combination of FSH Society 
Marjorie and Gerald Bronfman fellowship 
grants, Jacobs Family and Friends research 
fellowship grants, FSH Society Grant Delta 
Railroad Construction Company fellowship 
grant and a FSH Society Landsman Chari-
table Trust fellowship grant. 
RNA Interference Improves Myopathic Phenotypes in Mice 
Over-expressing FSHD Region Gene 1 (FRG1)
Molecular Therapy, 2011 July 5 
[epub ahead of print]
Wallace LM, Garwick-coppens se, Tupler R, harper sQ
Molecular, cellular, and Developmental Biology Graduate Program, The 
Ohio state university, columbus, Ohio, usA. center for Gene Therapy, The 
Research Institute at Nationwide children’s hospital, columbus, Ohio, usA.
Abstract:  Muscular dystrophies, and other diseases of muscle, 
arise from recessive and dominant gene mutations. Gene replace-
ment strategies may be beneficial for the former, while gene silenc-
ing approaches may provide treatment for the latter. In the last two 
decades, muscle-directed gene therapies were primarily focused on 
treating recessive disorders. This disparity at least partly arose be-
cause feasible mechanisms to silence dominant disease genes lagged 
behind gene replacement strategies. With the discovery of RNA 
interference (RNAi) and its subsequent development as a promising 
new gene silencing tool, the landscape has changed. In this study, 
our objective was to demonstrate proof-of-principle for RNAi therapy 
of a dominant myopathy in vivo. We tested the potential of adeno-
associated viral (AAV)-delivered therapeutic microRNAs, targeting 
the human Facioscapulohumeral muscular dystrophy (FSHD) region 
gene 1 (FRG1), to correct myopathic features in mice expressing 
toxic levels of human FRG1 (FRG1(-high) mice). We found that FRG1 
gene silencing improved muscle mass, strength, and histopathologi-
cal abnormalities associated with muscular dystrophy in FRG1(-high) 
mice, thereby demonstrating therapeutic promise for treatment of 
dominantly inherited myopathies using RNAi. This approach poten-
tially applies to as many as 29 different gene mutations responsible 
for myopathies inherited as dominant disorders.
[PubMed - as  supplied by publisher]
PMID:  21730972
 rAAv-shrNA systemic delivery to mouse model of FSHD
A POSSiBlE APPrOACH FOr trEAtiNG FSHD WitH rNAi tHErAPEUtiCS
. . . from page 1
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http://www.nature.com/mt/journal/vaop/ncurrent/full/mt2011118a.html
The following are selected excerpts from Wallace, Harper et al paper’s 
Discussion section:  “We used the FRG1(-high) mouse model in this 
study, which was initially developed to test the hypothesis that FRG1 
over expression was a primary pathogenic insult underlying FSHD. 
Although the progressive myopathy produced in these mice strongly 
supported this hypothesis, there have been some conflicting data 
arguing against the involvement of FRG1 in FSHD, or at least mini-
mizing its role as a primary pathogenic insult. Thus, it is fair to say 
that FRG1 is a controversial FSHD candidate gene.  Nevertheless, for 
this study, we were unconcerned with this ongoing debate, because 
our primary goal was to demonstrate proof-of-principle for RNAi 
therapy of dominant myopathies in general, and the FRG1-high line 
was useful as an outstanding model of dominant muscle disease. We 
reasoned that its involvement in FSHD, or lack thereof, was irrel-
evant to the goal of this study. We therefore developed a gene therapy 
strategy to knockdown pathological levels of human FRG1 in FRG1-
high mouse muscles. Here, we reported that AAV6-delivered artificial 
microRNAs reduced toxic FRG1levels and improved histological and 
functional muscle abnormalities associated with FRG1 over expres-
sion in mice. Our work therefore supports the therapeutic potential 
of RNAi therapy for dominant myopathies in general. In addition, it 
could be applied to FSHD, if additional evidence supporting FRG1 
involvement in the disease emerges; alternatively, our strategy could 
be modified to target other FSHD candidate genes, such as DUX4.”
AAV6-mediated Systemic shRNA Delivery Reverses  
Disease in a Mouse Model of Facioscapulohumeral  
Muscular Dystrophy
Molecular Therapy, 2011 August 9
Bortolanza s, Nonis A, sanvito F, Maciotta s, sitia G, Wei J, Torrente Y, Di 
serio c, chamberlain JR, Gabellini D
Dulbecco Telethon Institute and Division of Regenerative Medicine, san 
Raffaele scientific Institute, Milano, Italy
Abstract:  Treatment of dominantly inher-
ited muscle disorders remains a difficult task 
considering the need to eliminate the patho-
genic gene product in a body-wide fashion. 
We show here that it is possible to reverse 
dominant muscle disease in a mouse model 
of facioscapulohumeral muscular dystrophy 
(FSHD). FSHD is a common form of mus-
cular dystrophy associated with a complex 
cascade of epigenetic events following reduc-
tion in copy number of D4Z4 macrosatellite 
repeats located on chromosome 4q35. Several 
4q35 genes have been examined for their 
role in disease, including FRG1. Overexpres-
sion of FRG1 causes features related to FSHD 
in transgenic mice and the FRG1 mouse is 
currently the only available mouse model of 
FSHD. Here we show that systemic delivery 
of RNA interference expression cassettes in 
the FRG1 mouse, after the onset of disease, 
led to a dose-dependent long-term FRG1 knockdown without signs 
of toxicity. Histological features including centrally nucleated fibers, 
fiber size reduction, fibrosis, adipocyte accumulation, and inflamma-
tion were all significantly improved. FRG1 mRNA knockdown resulted 
in a dramatic restoration of muscle function. Through RNA interfer-
ence (RNAi) expression cassette redesign, our method is amenable to 
targeting any pathogenic gene offering a viable option for long-term, 
body-wide treatment of dominant muscle disease in humans.
PMID:  21829175
[PubMed - as supplied by publisher]
http://www.nature.com/mt/journal/vaop/ncurrent/full/mt2011153a.html
The following are selected excerpts from Bortolanza, Gabellini et 
al paper’s Discussion section:  “Although several intriguing FSHD 
candidates have been proposed, no single gene has been conclusively 
linked to FSHD development thus far. It was reported that the D4Z4 
repeat contains an ORF encoding a double homeobox protein named 
DUX4. DUX4 has been detected in FSHD-derived primary myoblasts 
but not in controls, suggesting that D4Z4 may directly affect disease 
progression through the aberrant production of DUX4.  Several func-
tional studies described extreme general toxicity for DUX4. Cellular 
toxicity of DUX4 coupled with very low DUX4 expression in human 
cells poses a difficult challenge for modeling the human disease in 
mice. However, if a DUX4 mouse model is produced, our approach 
could be adapted for DUX4 knockdown in muscle through retarget-
ing of the RNAi hairpin sequence to DUX4 mRNA.
 “A growing understanding of its function, strongly suggests 
that FRG1 overexpression plays an important role in FSHD. Based 
on these data, FRG1 inhibition would be expected to lead to a 
therapeutic benefit in FSHD. Hence, we have used the only available 
FSHD mouse model to provide a proof of principle with respect to 
the use of RNAi therapeutic approaches for FSHD. In this study, 
we demonstrated long-term, dose-dependent reduction in FRG1 
expression in all the muscles analyzed. Therapeutic benefits were 
observed in all of the mice treated with either low or high AAV6-
How rNAi works for FrG1 myopathy
t
. . . continued on page 26
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The Harper Lab has grate-fully received funding 
from the FSH Society in 
recent years for our work on 
understanding the function 
of the DUX4 gene in FSHD. I 
am honored to have the op-
portunity to update the FSH 
Society on our progress.
DUX4 is a transcription 
factor
Human beings have roughly 
25,000 genes that give rise 
to proteins. These proteins 
have diverse functions. 
Some, like collagen, are raw 
materials used to structur-
ally build cells and tissues. 
Others, like enzymes, may be 
used to help digest food and 
convert it to energy for powering our cells. The genes that encode 
these proteins are not always on or off in every cell, at every mo-
ment; control needs to be maintained over when, where, and how 
much these genes are expressed. To help accomplish this, cells 
use another group of proteins, called transcription factors, that 
switch other genes on or off in response to specific stimuli. The 
DUX4 gene, which has been recently implicated as a contributor to 
FSHD, produces a “transcription factor” protein. 
Our FSH Society-funded projects on DUX4
We, and others in the FSHD research field, hypothesized that 
DUX4 is involved in FSHD. DUX4 appears to be normally dor-
mant in muscle, but under specific conditions associated with 
FSHD, the gene can be turned on. Since it is a transcription factor, 
it can then turn on other genes that may not normally be ex-
pressed in muscle. If some of these genes were toxic, then DUX4 
itself would be toxic.
  
Project 1 August 2009
Our initial goals for our FSH Society-funded work were to: 1.) 
test if DUX4 was toxic to mammalian (mouse) muscle and, 2.) 
determine if this toxicity was related to its function as a transcrip-
tion factor. We indeed found that DUX4 was capable of damaging 
otherwise normal muscle, and that its ability to elicit this damage 
required transcription factor function. We then began trying to 
identify which toxic genes DUX4 could be activating to cause such 
damage. We found that DUX4 was stimulating genes involved in 
programmed cell death, which does not normally occur in healthy 
muscle cells. Our findings, together with many other published 
studies by other research groups, led us to conclude that DUX4 is 
Understanding the function of the DUX4 gene in FSHD  
Perspectives and updates from recently funded FSH Society grantees 
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by sCOtt Q. haRPeR, Ph.d.
The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio
toxic to mammalian mus-
cle because it can activate 
genes that ultimately lead 
to programmed cell death.
 We are happy to 
report that this work was 
recently published in the 
Annals of Neurology, and 
we have used this data 
to apply for additional 
funding from the National 
Institutes of Health and 
the Muscular Dystrophy 
Association. Moreover, 
this work represents a 
significant portion of 
the Ph.D. thesis of Ms. 
Lindsay Wallace, an Ohio 
State University gradu-
ate student in the lab. We 
were honored that Ms. 
Wallace was chosen as the Outstanding Pre-Doctoral Trainee at 
the 60th meeting of the American Society of Human Genetics last 
year for this work. We are therefore grateful that the FSH Society 
and its donors have played an important part in the training of a 
promising young scientist, who will continue working in the field 
throughout her career. 
Project 2 August 2010
We are continuing to work on understanding the pathways DUX4 
controls. But we also turned an eye toward understanding how 
DUX4 could account for the pattern of muscle involvement often 
associated with FSHD. In other words, if DUX4 is involved in 
FSHD, how does it affect some muscles more than others?  The 
most obvious idea is that DUX4 itself is turned on only in affected 
muscles. As we already mentioned, transcription factors are pro-
teins that turn other genes on and off. They accomplish this by ac-
tivating a switch, called a “promoter.”  We therefore set out to test 
if DUX4’s promoter was active specifically in muscles affected by 
FSHD. This project is ongoing and we are beginning to see some 
interesting results, but we do not yet have conclusive data that we 
can confidently share with the greater FSHD community. We are 
excited to report our findings once we have a more complete story. 
 Ultimately, our goal is to better understand how DUX4 par-
ticipates in the FSHD disease process, since this information is 
essential if we want to develop treatments for the disease. The FSH 
Society’s support has been critical for my pursuing this goal, and 
also in my lab’s growth and development in general over the last 
several years. As I mentioned, this support has included not only 
research funding but also the training of a new generation of scien-
tists. For this, we are eternally grateful.
Drs. takako Jones, Peter Jones and lindsay Wallace (right) discuss research advances 
at the FSH Society 2010 FSHD international research Consortium
FSH Watch
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The main subject of my team is the im-plication of chromatin and epigenetic 
changes in human diseases, from rare to 
common diseases. My research group is 
located in Marseilles, in the laboratory of 
Medical Genetics and Functional Genomics 
directed by Nicolas Lévy. My research project 
on FSHD began in 2003 in Lyon (France). In 
2009, I obtained a one-year grant from the 
FSH Society (Delta Railroad Construction, 
Inc.), which was of tremendous importance 
in the creation of my research team in Mar-
seilles and the development of new aspects 
of my research project.
 FSHD is undoubtedly a very exciting 
albeit challenging disease to work on for any 
one interested in epigenetics. With regard 
to FSHD, we mainly focus on the role of 
chromatin changes and positioning of the 
locus within the nuclear space on the disease 
onset progression and penetrance. Since the 
discovery of the partial deletion of the D4Z4 
repetitive DNA at the end of the long arm of 
chromosome 4 in patients with FSHD, the 
disease mechanism underlying FSHD has 
remained puzzling. Close examination of the 
4q35 region greatly increased our under-
standing of FSHD onset with the recent 
breakthrough on the regulation of the DUX4 
gene, contained within the D4Z4 repeats, 
proposed as a key player in FSHD.
 In my initial work, we put a lot of effort 
in creating models mimicking the organiza-
tion of the 4q35 locus either in patients or 
in healthy situations and tried to decipher 
the biological function of the D4Z4 repeat 
on chromatin regulation. As any model, ours 
has limitations and we now try to address 
new questions using cells from patients. This 
has been feasible during the last months 
thanks to a fruitful collaboration with the 
departments of Neurology and Genetics at 
La Timone Children’s Hospital in Marseilles, 
a reference center in France for the diagnosis 
and exploration of FSHD patients. With the 
idea in mind that any exception to the rule 
might help in understanding the pathology, 
we tried to collect samples from atypical 
FSHD cases (twin sets, families with variable 
Understanding the role of chromatin changes and positioning  
of the locus within the nuclear space in FSHD  
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by FRedeRiQUe MaGdinieR, Ph.d.
Faculté de Médecine de la Timone, Marseille, France
penetrance, FSHD2 patients). Although not 
very productive in term of publications, the 
last nine months have been very active in 
term of samples collection and preparation 
of primary cell lines (myoblasts, fibroblasts 
isolated from biopsies and recently induced 
pluripotent cells) from FSHD patients and 
controls. Now, we want to learn more on 
these samples by comparing diseased and 
unaffected muscles at the level of chromatin 
fiber and compare when feasible muscle 
biopsies with primary myoblasts in culture. 
With regard to induced pluripotent cells, 
adult pluripotent cells (fibroblasts obtained 
from a skin biopsy) can be reprogrammed to 
a pluripotent state, i.e. with the capacity to 
be differentiated into new cell lineages. 
Adult pluripotent stem cells (fibroblasts obtained from a skin biopsy) can be reprogrammed into induced pluripotent 
stem cells (iPS)
 These different types of cells are a very 
valuable resource, which will help us not 
only to obtain a better understanding of the 
disease but can also be used to develop and 
test therapeutic molecules for FSHD. 
 All cells in a given individual share the 
same genetic background. However, all 
genes do not necessarily lead to the produc-
tion of a protein in every cell. To achieve 
this fine ON/OFF tuning, cells are regulated 
by epigenetic mechanisms, which can be 
defined as changes in gene expression caused 
by mechanisms other than changes in the 
underlying DNA sequence. Different modi-
fications contribute to epigenetic regula-
tions such as DNA methylation, The D4Z4 
repeat contraction coincides with the loss 
of repressive chromatin marks in the 4q35 
region and the transcriptional de-repression 
of the DUX4 gene in skeletal muscle. In 
some cases, the opening of the chromatin 
structure is independent from a contraction 
of the D4Z4 repeat array (FSHD2). Based on 
our promising preliminary data on patients’ 
samples, we are continuing the analysis of 
the epigenetic changes occurring at the 4q35 
locus in pathological samples. We try to 
make a link between changes in DNA methy-
lation and DUX4 expression in FSHD1 and 2 
patients. We are using iPS cells to investigate 
how epigenetics marks are deposited onto 
the D4Z4 repeat in different contexts. We are 
also pursuing the characterization of the long 
distance chromatin interactions involving the 
4q35 gene within the nuclear space. 
We mainly focus on the role  
of chromatin changes and  
positioning of the locus within the 
nuclear space on the disease onset 
progression and penetrance. Since 
the discovery of the partial deletion 
of the D4Z4 repetitive DNA at the 
end of the long arm of chromosome 
4 in patients with FSHD, the disease 
mechanism underlying FSHD has 
remained puzzling. 
‘‘
’’
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FSHD is an inherited neuromuscular disorder. Recent scientific advances have provided valuable insights into how genetic change 
(such as deletion of the D4Z4 repeat region on chromosome 4 for 
Type 1 FSHD) can adversely affect muscle development, leading to 
progressive wasting and weakness of the face, shoulder girdle, upper 
arms, abdominal, and lower limbs musculatures. Among individuals 
with genetically confirmed diagnosis of FSHD, there is a wide 
spectrum of expression of the disease, ranging from being unaffected 
to wheelchair-dependency because of significant weakness. Although 
FSHD typically manifests during the second or third decade of life 
with facial involvement, scapular winging, and limitation in shoulder 
and arm movements, atypical features with relative facial sparing 
and predominantly lower extremities weakness have been described. 
Environmental factors and other genetic modifiers likely play 
important roles in the variable expression of FSHD.
 Less is known regarding the early childhood form of FSHD 
because it is uncommon. Infantile (onset less than 11 years of age) 
FSHD makes up about five percent of the total FSHD population, 
and affected individuals may have a more severe phenotype as well 
as extra-neuromuscular manifestations such as cognitive disability, 
seizures, visual impairment, and hearing deficit. Affected children 
may present with low muscle tone since infancy, with global 
developmental delay and poor growth due to feeding difficulties. 
Orthopedic complications such as hip displacement and spinal 
deformities may compound the muscle weakness leading to loss of 
independent ambulation at a young age. Even though early infantile 
Creating a multicenter collaborative study on the clinical features,  
expression profiling, and quality of life of infantile onset FSHD  
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by Jean K. Mah, M.d., M.sc., FRCPC
Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada
form of FSHD may be associated with smaller fragments size of D4Z4 
repeats, anticipatory planning can be challenging, as it may arise 
from spontaneous mutation with no other affected family members. 
Because it is less common, the physical and psychosocial impact 
of infantile onset FSHD has not been formally assessed. As well, 
a prospective evaluation protocol for the natural history has been 
developed for adults but not for children with FSHD.
 Therefore, the main objectives of this study are: 1.) to establish 
a standardized muscle testing protocol including both manual 
and quantitative muscle testing as well as function testing for use 
in children and adults with infantile onset FSHD; 2.) to describe 
the clinical phenotypes of infantile FSHD, separately for the early 
infantile group (onset before age five) and the late onset group (onset 
between five and ten years of age); 3.) to evaluate the impact of 
physical impairment, secondary health conditions, activity limitations 
and disability caused by FSHD on health-related quality of life and 
disability across different age groups; and 4.) to explore potential 
genetic modifiers of clinical phenotypes and disease progression in 
infantile FSHD by first comparing expression profiles in a most severe 
phenotype subgroup of patients to a mildest phenotype subgroup of 
patients and identifying genes and pathways that potentially modify 
the phenotypes using microarrays. The differentially regulated genes 
and pathways will then be validated using gene transcription and 
protein assays. The correlation between gene expression and disease 
severity will be determined. 
. . . continued on page 26
  
the fsh soCiety: Who We aret
The Facioscapulohumeral muscular dystrophy Society (the FSH) 
Society is a world leader in combating muscular dystrophy. Since 1997, 
it has provided nearly three million dollars in seed grants for pioneering 
FSHD research projects and education worldwide and created an inter-
national collaborative network of patients and researchers. The Society 
relies entirely on private grants, donations and grassroots philanthropy. 
Its purpose is to increase the awareness, understanding and conduct 
research and education on the most prevalent muscular dystrophy 
affecting men, women and children called FSHD.
 The FSH Society offers basic research grants, research and post-
doctoral fellowships to support research relevant to understanding the 
molecular genetics and cause of FSHD on an ongoing and ad-hoc basis. 
The FSH Society Scientific Advisory Board (SAB) provides strategy 
for FSHD research, recruits researchers, selects research proposals, 
evaluates research proposals, grants fellowships and monitors ongoing 
projects and research opportunities. The Society also organizes an 
annual symposium for researchers worldwide that yields major gains in 
understanding FSHD. FSH Society grants have led to hundreds of publi-
cations acknowledging Society support in top-tier scientific journals.
 In accordance with its primary purpose of serving the FSHD com-
munity in the United States and abroad, the FSH Society has brought 
together through education, patient-researcher network meetings, sup-
port group meetings, peer-support, and advocacy to more than 5,000 
FSHD-affected families committed to working cooperatively. Through 
the FSH Society, its electronic bulletin board, social networking, chat 
room and quarterly newsletter, the FSH Watch, FSHD patients have 
found ways to be useful to medical and clinical researchers working on 
their disease. The support patients receive from one another through 
sharing their common experience is invaluable and immeasurable. The 
FSH Society acts as a clearinghouse for information on FSHD  and on 
potential drugs and therapies designed to alleviate the effects of the 
disease. It fosters communication among FSHD patients, their families 
and caregivers, charitable organizations, government agencies, indus-
try, scientific researchers, and academic institutions.
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vOlUNtEErS NEEDED FOr 
MUSClE BiOPSY StUDY   
Please consider making the valuable 
gift of muscle tissue and blood samples 
to advance research efforts on FshD. 
Muscle samples are in extremely short 
supply and tissue donors are needed. The 
Fsh society and Johns hopkins school 
of Medicine, as part of the NIh-funded 
Boston Biomedical Research Institute 
sen. Paul Wellstone Muscular Dystrophy 
cooperative Research center for FshD, 
are recruiting volunteers with FshD and 
their first degree unaffected relatives 
(for example: parent, brother, sister, or 
child of a person with FshD) to provide 
muscle and blood samples. The collected 
samples will be used to learn more about 
how individuals with FshD differ from 
individuals with normal muscle, in the 
search of treatments and a cure for FshD.
 To date, more than 60 individuals 
in over 30 families with FshD-affected 
volunteers and their unaffected relatives 
have participated in the Wellstone center 
for FshD research study. More groups 
are needed to help meet the goal of 
increasing the sample library to cover 
a wider range of FshD. As of July 2011, 
the research study has increased in 
sample size from a target of 66 to 100 
participants. Researchers at the Wellstone 
center have asked the Fsh society to 
reach out especially to individuals with 
suspected FshD related hearing loss, 
suspected FshD related retinal issues, and 
FshD-affected individuals of ethnic and 
racial minorities, but all are welcome and 
needed.
 In order to determine eligibility, you 
will need to provide a copy of your genetic 
testing diagnostic result and medical 
records indicating FshD diagnosis. If you 
have suspected FshD related hearing loss, 
FshD related retinal issues, are an FshD 
patient or individual of minority race or 
ethnicity, please contact us at the contacts 
below. This additional information will not 
adversely affect your previous inquiry or 
consideration for inclusion into the study.
 Go to www.fshsociety.org for more 
information, or contact Ms. Doris Walsh 
at the Fsh society, 617-658-7877 or doris.
walsh@fshsociety.org or call Genila Bibat, 
M.D., at Johns hopkins school of Medicine 
– Neurology, 707 North Broadway, 
Baltimore, MD 21205 at 443-923-2697.
     R e s e a R C h  s t U d i e s
Editorial note: FsH Watch will occasionally 
highlight neuromuscular clinics that we believe might 
be of interest to patients and their families. This 
issue includes programs in Maryland and New York.
The Center for Genetic Muscle Disorders at the Kennedy Krieger Institute was founded by Kathryn 
Wagner, M.D., Ph.D., in 2009. The Center is a part of 
Kennedy Krieger’s new outpatient center, thoughtfully 
designed in partnership with, and for, those with 
disabilities. Although the building and Center are new, 
Dr. Wagner is no newcomer, having cared for patients 
with FSHD for over a decade at Johns Hopkins prior 
to moving her practice to Kennedy Krieger. She 
also serves on the Scientific Advisory Board for the 
FSH Society and is a principal investigator in the Senator Paul Wellstone Muscular Dystrophy 
Cooperative Research Center project entitled “Biomarkers for Therapy of FSHD.”
 The Center for Genetic Muscle Disorders provides current interdisciplinary clinical care for 
patients by experts in muscle disease and also provides an environment for research programs 
that develop better and novel therapeutics to treat these disorders in the future. The collective 
expertise of the Center’s staff provides these patients with an informed diagnosis and prognosis, 
as well as a unique perspective on how the disease will impact their day-to-day life. As leaders 
in their fields, medical professionals are able to work with patients to find practical solutions 
to the specific problems they are experiencing as well as work to slow the progression of the 
disease. Specialists in the field of neurology, rehabilitative medicine, social work and genetics 
counseling are available at every clinic visit. In addition, for those patients with complex medical 
needs, pulmonologists and endocrinologists participate in the clinic as needed. Enabled by the 
collaboration among Kennedy Krieger’s various programs, patients who visit the Center also have 
easy access to a variety of clinical services to help manage their symptoms and improve their 
quality of life, such as audiology, speech therapy, aquatic therapy and assistive technology. 
 A unique strength of the Center for Genetic Muscle Disorders includes the option for 
participants to be involved in novel therapies and research.  Kennedy Krieger is currently 
enrolling subjects with FSHD in a biomarker study (see sidebar, at left) as part of the NIH-
funded, FSHD Wellstone centered at Boston Biomedical Research Institute. Previously, Dr. 
Wagner led a trial of the myostatin inhibitor, MYO-029, one of the first trials of a novel drug in 
FSHD. She has been a strong advocate for more clinical trials in FSHD and continues to work to 
bring industry attention to the disease.
 Another strength of the Center is the ability for patients to remain in the program through 
the transition from childhood to adolescence and through adult life. Dr. Wagner is an adult 
neurologist who sees patients of all ages. Neurologist Diana Escolar, M.D., cares for pediatric 
neuromuscular patients and neurologist Doris Leung, M.D, cares for primarily adult patients 
with muscular dystrophy. Kennedy Krieger, a renowned institute for children with physical and 
developmental disabilities, also serves adults with a range of disorders affecting the brain and 
musculoskeletal system including adult onset muscular dystrophy, spinal cord injury, cerebral 
palsy and spina bifida.  There is an active group of those with FSHD who participate in the 
clinic who convene outside of clinic to discuss common challenges and solutions as well as 
opportunities for the future. 
 For an appointment call Angie Lasseth at 443-923-9525. The clinic address is 801 North 
Broadway, Baltimore.
Kennedy Krieger Institute, Center for Genetic 
Muscle Disorders  
An interdisciplinary clinic dedicated to the diagnosis and treatment of FSHD
     C l i n i C a l  M a n a G e M e n t
by KathRyn WaGneR, M.d., Ph.d.
Kennedy Krieger Institute, Baltimore, Maryland
kathryn Wagner, M.D., Ph.D., Director, kennedy 
krieger institute, Baltimore, Maryland with FSHD 
patients lilleen and Collin Walters 
FSH Watch
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I started studying FSHD about four years ago, at the beginning of my Ph.D. in Cellular and Molecular Biology at the Univer-
sità Vita Salute San Raffaele in Milan, Italy, under the supervi-
sion of Dr. Davide Gabellini, who has a long-lasting experience 
in the FSHD field. Dr Gabellini’s lab studies FSHD at different 
levels. Among the various projects available, I found myself 
extremely interested in the elucidation of the initial steps that 
characterize FSHD pathogenesis. In particular, I wanted to bet-
ter understand the molecular mechanism linking the primary 
FSHD genetic defect (loss of D4Z4 repeats) to the pathology.
 For the first three years of my Ph.D. I was financed by the University, while 
for the last 18 months of my Ph.D. work I have been generously supported by 
the FSH Society, which awarded me a New York Symphony and Song Fellow-
ship Grant. Recently, I defended my Ph.D. thesis focused on molecular aspects 
of FSHD with success.
 At the beginning of my project, it was already known, thanks to studies 
performed by other groups, that FSHD patients display a reduced accumulation 
of several repressive marks at the disease-associated locus (4q35). Indeed, it has 
been proposed, and nowadays there is increasing evidence strongly support-
ing it, that an inefficient repression in FSHD patients leads to the inappropriate 
over-expression of 4q35 gene(s). Among these, DUX4 is currently the leading 
candidate for FSHD development. However, little is known about how the de-
regulation of 4q35 genes occurs.
 The research I conducted focused on the characterization of the molecular 
events driving the over expression of FSHD candidate genes in the disease. 
In particular, we found that D4Z4 is a target of the Polycomb Group (PcG) of 
proteins, factors with crucial cellular functions that act to shut off gene expres-
sion. Interestingly, FSHD patients show reduced enrichment of PcG proteins 
at D4Z4, suggesting that a weakening of PcG repressive function could be 
involved in increased expression of 4q35 genes. I found that deletion of D4Z4 
repeats is associated to the production of a chromatin-associated, 4q35-local-
ized long non coding RNA by the region immediately proximal to the repeat 
array. We named this RNA DBE-T. Remarkably, functional studies revealed that 
DBE-T is required for the over-expression of FSHD candidate genes. Indeed, by 
reducing the expression of DBE-T we could counteract the over-expression of 
4q35 genes, including DUX4.
 Compared to other genetic diseases, FSHD is extremely complicated as it 
involves novel cellular mechanisms that are challenging to study. Nevertheless, 
efforts by several groups are leading to important discoveries that are helping to 
shed light on FSHD pathogenesis. Our work is helping to unveil the pathway 
originating with D4Z4 deletion and leading to over-expression of FSHD candi-
date genes. By doing so, it contributes to the FSHD cause, adding new impor-
tant pieces to the puzzle. Indeed, this study led to the identification of novel 
players whose action is potentially crucial for FSHD pathogenesis. Importantly, 
our results go beyond single candidate genes-generated defects. It is tempting 
to speculate that DBE-T might be a valid therapeutic target in order to achieve a 
general normalization of 4q35 genes expression in FSHD.
 Work made possible by a FSH Society New York Festival of Music research 
fellowship grant.
Unveiling D4Z4-connected pathways  
leading to over-expression of FSHD genes 
Perspectives and updates from FSH Society grantees
     R e s e a R C h
by daPhne CaBianCa, Ph.d
Università Vita Salute San Raffaele, Milan, Italy
Daphne Cabianca, 
Ph.D.
isolating a biomarker for  
fshd therapeutics
t
One of the aims of our FSHD research program is 
to identify biomarkers for FSHD. Essentially these 
biomarkers are proteins and nucleic acids that are 
aberrantly expressed in FSHD muscle as compared 
with muscle in unaffected individuals. The ratio-
nale for this research is two-fold. First, biomarkers 
may in fact be the causal agents for pathology and 
identifying them may provide targets for thera-
peutic development. Secondly, FSHD biomarker 
discovery is important so that when treatments 
are developed for FSHD, we will have something 
measurable to indicate if the treatments are being 
effective. Finding consistent biomarkers for FSHD 
is vital.
 For this FSHD biomarker project we investigat-
ed protein expression in two cell lines derived from 
FSHD muscle and compared with two cell lines 
from unaffected, unrelated individuals. We found a 
previously unknown protein that was developmen-
tally over-expressed in both FSHD lines compared 
with unaffected cells. This data formed the founda-
tion of our proposal to identify and characterize 
this protein. However, as interesting as this may 
be, there were legitimate concerns about basing 
this work on such a small sampling of cells (two 
FSHD and two control). Thankfully the FSH Society 
Scientific Advisory Board approved partial funding 
for the project and requested that we investigate 
more FSHD and control cells to shore up our 
preliminary finding. Fortunately we have recently 
moved our laboratory to the Boston Biomedical 
Research Institute where the Paul D. Wellstone 
Muscular Dystrophy Cooperative Research Center 
for FSHD is based. Since our move we have been 
able to utilize the unique collection of myogenic 
cells obtained from families of FSHD patients and 
their unaffected first-degree relatives to validate 
our initial biomarker hypothesis. Using these cells 
we have found that this unidentified protein is 
similarly developmentally over-expressed in all of 
the Wellstone FSHD cell lines we have analyzed 
compared with matched control unaffected cells. 
This data strongly suggests that we have indeed 
found a biomarker for FSHD cells and we are now 
eager to identify and further characterize it in the 
near future.
updates from recently funded  
Fsh society grantees
by JessiCa Chia-yUn sUn, Ph.d., and 
PeteR l. JOnes, Ph.d.
Boston Biomedical Research Institute (BBRI)
Watertown, Massachusetts
FSH Watch
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Alternative splicing as an important layer of gene misregulation  
in FSHD and infantile FSHD   
Perspectives and updates from FSH Society grantees
by yi XinG, M.d., Ph.d
University of Iowa, Iowa City, Iowa
Proteins are encoded by mRNAs which, on average, are approximately 2,500 bases 
long. However, RNA initially transcribed from 
genomic DNA (pre-mRNA) can be over 100 
kilobases in length. To attain a final form, 
pre-mRNAs must be processed: interven-
ing sequences (introns) must be removed 
and exons (which contain the protein code) 
must be defined and concatenated. This 
searching and joining process is called RNA 
splicing and is performed by a huge cellular 
machine—the spliceosome—that contains 
over 100 proteins. Depending on the cellular 
environment—determined by the tissue type, 
developmental stage, or extra-cellular cues—
different exons will be recognized in a single 
pre-mRNA. This crucial regulatory process, 
termed alternative splicing, can produce 
multiple, distinct mRNA products from a 
single gene, allowing one gene to generate a 
myriad of proteins (see Figure). Splicing must 
be tightly regulated in order to produce the 
correct (functional) gene product. Genetic 
mutations that disrupt splicing cause a broad 
range of human diseases, including cancers, 
neurodegenerative diseases, and certain types 
of muscular dystrophy. One candidate gene 
of particular interest in the pathophysiol-
ogy of FSHD and infantile FSHD (IFSHD) is 
FRG1 (FSHD region gene 1). FRG1 is located 
in close proximity to the D4Z4 region and 
encodes a component of the spliceosome. 
Important work by Dr. Davide Gabellini and 
colleagues showed that transgenic mice selec-
tively overexpressing FRG1 in skeletal muscle 
develop phenotypes that resemble FSHD in 
human patients. This raises the possibility of 
a global alternative splicing defect in FSHD/
IFSHD.
 Dr. Xing’s laboratory at the University of 
Iowa Carver College of Medicine studies the 
regulation of alternative splicing in healthy 
and diseased cells. In collaboration with Dr. 
Katherine Mathews at the University of Iowa 
Wellstone Muscular Dystrophy Cooperative 
Research Center, his group is differentiat-
ing primary skin fibroblast or myoblast cell 
cultures collected from FSHD/IFSHD patients 
and healthy individuals into muscle cells. 
On RNAs extracted from these differentiated 
muscle cells, the scientists are using a variety 
of cutting-edge high-throughput genomic 
technologies to examine the activities of pro-
teins that regulate splicing, as well as the al-
ternative splicing patterns of all human genes 
in normal and diseased cells. For example, by 
deep sequencing of mRNA molecules using 
ultra-fast next-generation DNA sequencers, 
it is now possible to generate hundreds of 
millions of RNA sequences from any patient 
sample to globally analyze gene expression 
and alternative splicing at the nucleotide 
resolution. The scientists hope that these 
studies will reveal splicing as an important 
layer of gene misregulation in FSHD/IFSHD, 
and find novel genes and molecular path-
ways amenable to therapeutic development. 
Importantly, by comparing FSHD and IFSHD 
cells, scientists might gain significant novel 
insight into the molecular mechanism under-
lying the early onset and severe symptoms of 
IFSHD. Editorial note:  Many of the primary 
skin fibroblast or myoblast cell cultures were 
collected from FSHD/IFSHD patients and 
healthy individuals who attended the 2008 bi-
ennial FSH Society Patient Researcher meeting 
in Coralville, Iowa.
  Work is made possible by a FSH Society 
Aubrie Lee Family Research Grant for Infantile 
FSHD & Fire Island & Fabiola Bertinotii 
research fellowship grant
investigating gene-expression differences in fshd stem cells as they developt
FSH Watch
various types of alternative splicing being considered in FSHD
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We are studying primary cells from muscles of FSHD-affected individu-
als, as well as induced pleuripotent stem (IPS) cells derived from these 
muscle cells. IPS technology is a relatively recent development in the 
stem cell field that allows cells from adults to be “reprogrammed” in 
vitro so that they resemble embryonic stem (ES) cells. IPS cells are es-
sentially ES cells but since they are not derived from embryos their use 
is not controversial.  Importantly, they have the potential to differentiate 
into any cell type, and we have used FSHD IPS cells to generate cells of 
different types, and at different stages of differentiation.  Support from 
the FSH Society is allowing us to investigate gene-expression differenc-
es, that may give insight into the cause of FSHD, and thereby helping 
us to understand in which cells and at what stage in their development 
changes occur that may cause this disease.  With the FSH Society’s 
support we now have an individual doing our project’s bio-informatics 
analysis and we hope to have results that could be discussed in the 
near future.  Work made possible by a FSH Society New York Festival of Music research fellowship grant
by MiChael KyBa, Ph.d
Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota
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The FSH Society has two rounds of grant applications each year, with deadlines in February and August. Grant applications are 
thoroughly analyzed and vetted by the SAB. For a description of 
the review and approval process, see box left.
 The Scientific Advisory Board (SAB) met in November to 
review grant applications received for the August 2010 round of 
FSH Society grants funding. Below is a list of the funded projects, 
including project descriptions as submitted by grant applicants.
February 2011 round
 
1.  Antisense strategies against DuX4 as therapeutic approaches  
 for FshD
eugénie Ansseau, Ph.D./Alexandra Belayew, Ph.D.
universite de Mons, Mons, Belgium
$70,500 over 2 years, $25,000 year 1, $45,500 year 2
summary (Provided by Applicant): FSHD is a muscle degeneration 
disease genetically linked to contractions of the D4Z4 repeat array 
on the 4q35 subtelomeric region. Our group has identified the 
double homeobox 4 (DUX4) gene within each unit of the D4Z4 
repeat array and shown that the encoded protein was expressed 
in primary myoblasts and biopsies of patients with FSHD but not 
in non-affected individuals. We found that the only stable DUX4 
messenger RNAs derive from the last unit and extend to the 
flanking pLAM sequence that provides a polyA addition signal. 
This signal is required to develop FSHD as independently con-
firmed by an eight-laboratory consortium which studied genetic 
polymorphisms in hundreds of patients and thousands of healthy 
individuals. In aggregate our collaborative studies with four dif-
ferent groups have shown that the DUX4 protein is a transcrip-
tion factor that targets a large set of genes, some of which encode 
other transcription factors that in turn target additional genes. 
Globally, DUX4 activation at the FSHD locus initiates a transcrip-
tion cascade leading to muscle atrophy, inflammation, decreased 
differentiation potential and oxidative stress, the key features of 
the disease. By differential protein, RNA and gene studies we keep 
identifying additional FSHD biomarkers and define whether they 
are direct or indirect DUX4 targets. 
 Strikingly, we found that DUX4 expression in human myoblast 
induces an atrophic myotube phenotype and atrophy markers. 
The rationale of our on-going project is that inhibition of DUX4 
expression should prevent the global gene deregulation process 
and allow muscle regeneration in patients. We have first devel-
oped small inhibitory RNAs (siRNAs) and conditions to suppress 
DUX4 protein expression either in primary myoblast cultures 
transfected with a DUX4 expression vector, or in primary FSHD 
myoblasts. Addition of DUX4 siRNA to FSHD myoblasts allowed 
recovery of a normal myotube phenotype with a decrease of 
atrophy markers. We have started a collaboration with Prof. Steve 
Wilton (ANRI, Australia) because of his expertise in the exon 
FSH Society grants recently awarded  
February 2011 and August 2010 rounds
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by Fsh sOCiety
Watertown, Massachusetts 
t
fsh society research fellowship grants 
since last newsletter
t
Since 1998, the FSH Society has transformed FSHD research 
by providing grants for vital start-up funding for investigators in 
FSHD and research projects on FSHD. The FSH Society has two 
rounds of grant applications each year, with deadlines in Febru-
ary and August. Grant applications are thoroughly analyzed 
and vetted by the SAB. An initial letter of intent is submitted, 
which is reviewed by Professor David Housman, Chair of the 
SAB.  If a letter of intent is accepted, the applicant submits a 
full application. The main section where researchers describe 
the proposed work and workflow is around 12 pages long.  
Upon receipt of all full grant applications for a particular round, 
Professor Housman assigns teams of two or more members of 
the SAB to critique each proposal.  Any potential conflicts of 
interests are noted, and SAB members who may have a conflict 
are not assigned to review, and do not vote on, the particular 
proposal. The two reviewers review the application in depth and 
provide a detailed written description and recommendation to 
the other members.  Initial critiques are due within three weeks 
of the assignment and a full meeting of the SAB is held around 
two weeks thereafter. Grant applications are reviewed and 
voted upon by the entire SAB, with discussion led by the two 
primary reviewers.  SAB recommendations for approved ap-
plications are then sent to the Society’s Board of Directors for 
a vote. When the SAB disapproves an application, it provides 
the applicant with a detailed description of the reasons for 
disapproval, and the applicant may resubmit the application 
for consideration in a later round. SAB members and the chair 
serve without pay.
 Upon acceptance by the Society’s board, the grantee 
receives a letter of acceptance and a grants policies and 
procedures document. The grantee is then asked for written 
confirmation indicating their intention of accepting or declin-
ing the fellowship knowing that the grant is administered in 
accordance with the FSH Society’s policies document. It is 
understood that the funds awarded have not been provided 
for any other purpose than research on FSHD. The grantee is 
asked to reply within two weeks where upon a check is issued 
in advance for the first six months with equal installments to 
follow at subsequent six month intervals based on review of 
requested progress reports.
 The milestones and insights gained are significant. The 
fellowship program allows innovative and entrepreneurial 
research to develop, prove successful, and ultimately to attract 
funding from large funding sources such as the US National 
Institutes of Health (NIH) and large private sources. We are 
very pleased to list the grantees funded in the February 2011 
and August 2010 cycles. You can also read more about FSH 
Society funded research projects by going to www.fshsociety.
org clicking on the “Research’ menu tab at top of page and then 
selecting “Research Fellows & Grantees” in the left hand verti-
cal navigation menu.
continuing to make progress in 
understanding and treating FshD
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will be assessed. This work will contribute to the understanding of 
the role of DUX4 in vivo, thus providing a better understanding of 
FSHD pathogenesis. 
 The proposed project will be completed following 2 specific aims: 
specific Aim 1: Optimization of the FSHD humanized mouse 
model. We will improve results obtained in preliminary experiments 
by designing more efficient transplantation strategies. In order to 
fully interpret the disease model, we will seek to increase the amount 
of muscle formed from implanted human cells, by devising more ef-
ficient transplantation strategies. The cell repository of the BBRI Well-
stone Center provides access to freshly isolated FSHD and their ap-
propriate control muscle cells sorted for CD56 expression, which are 
expected to have particularly high engraftment potential. However, 
the timing between the toxin injection and the cell injection, as well 
as depletion of endogenous satellite cells by irradiation of the mouse 
legs, may affect the ability of implanted cells to regenerate the murine 
muscle and will be optimized during this aim. Upon establishment of 
an effective mouse model, we will look for disease characteristics, as 
described in Specific Aim 2. 
specific Aim 2: Characterization of the FSHD humanized mouse 
model to evaluate the role of DUX4 during in vivo muscle regenera-
tion. The model obtained in Specific Aim 1 will be characterized by 
establishing differences between the fibers generated from FSHD cells 
and fibers from their appropriate control cells in injected muscles. 
Recent breakthroughs in the field suggest that DUX4, a gene identi-
fied inside D4Z4 repeats, expresses a toxic protein in the muscles 
of patients with FSHD, thus causing the disease. DUX4 may have 
a normal role during development and the FSHD pathology might 
involve incomplete developmental silencing of DUX4. However, the 
precise molecular and cellular mechanisms involving DUX4 remain 
to be uncovered. The BBRI Wellstone Center, currently investigating 
DUX4 expression in muscle samples from its cohort collection, has 
been able to detect DUX4 transcripts in FSHD samples, and these 
cohorts will be selected for the generation of the humanized FSHD 
mouse model. Initially, the expression of DUX4 at the mRNA and/
or protein levels will be assessed in FSHD- and control transplanted 
muscles. This will be followed with experiments designed to compare 
the biological characteristics of the resulting muscle fibers. Finally, 
we will develop a dynamic approach to investigate the current DUX4 
model in following the evolution of the engrafted fiber over time 
using in vivo bioluminescence live imaging. Murine models surpass 
in vitro limitations due to their ability to reproduce complex in vivo 
environment thereby providing a deeper understanding of disease 
mechanisms. Our model for creating humanized FSHD fibers in 
murine muscle will recapitulate the mechanisms of pathological 
fiber formation in vivo, allowing us to fully characterize the disease 
progression and test potential therapeutic agents.
 
A FSH Society New York Festive Evening of Music research fellowship 
grant
FSH Society grants recently awarded  
February 2011 and August 2010 rounds
skipping therapeutic approach with antisense oligonucleotides 
(AOs) in Duchenne muscular dystrophy. Prof. Wilton provided 
us with 7 AOs directed against various parts of the DUX4 mRNA 
characterized in our group: the aim was to either block translation 
or induce mRNA degradation to prevent DUX4 protein expres-
sion. We were able to identify conditions for selective DUX4 inhi-
bition by 3 AOs as done for the siRNAs above in human primary 
myoblast cultures. Moreover DUX4 mRNA inhibition also affects 
the expression of several FSHD markers such as μ-crystallin, 
β-catenin and TP53. These results constitute a proof of concept in 
myoblast cultures that DUX4 inhibition might reverse the FSHD 
phenotype. In the present project we want to validate these results 
by other techniques (RNA and protein expression profiling) and 
to test the effect of these AOs and siRNA in mouse models in vivo.
A FSH Society New York Festive Evening of Music research fellowship 
grant
 
2.  humanized mouse model for the study of Facioscapulohumeral  
 Dystrophy
Marietta Barro, Ph.D./charles P. emerson Jr., Ph.D.
Boston Biomedical Research Institute, Watertown, Massachusetts
$40,000 over 1 year
summary: FSHD is genetically caused by the contraction of D4Z4 
DNA repeats located on chromosome 4 in 4q35. Although the 
genetic defect was identified 20 years ago, the exact molecular 
mechanism causing the disease is unknown, and there is cur-
rently no mouse disease model. To provide such a valuable tool, 
we will develop a humanized mouse model for FSHD, obtained 
by the engraftment of FSHD patient-derived myoblasts into mouse 
muscle. Engrafted human cells are able to form muscle fibers in 
the host mouse muscle, thus allowing pioneering studies in an in 
vivo context. Because of the dominant nature of FSHD, we hypoth-
esize that the engrafted fibers will display a disease phenotype and 
recapitulate pathological molecular mechanisms associated with 
FSHD that will allow us to study the development of the disease. 
Our preliminary studies have already established the feasibility of 
this project. Through the cell repository of the Boston Biomedical 
Research Institute (BBRI) Wellstone Center, we have the unique 
opportunity to access early passage myoblast cells from cohorts of 
FSHD probands and their appropriate controls, i.e., a first degree 
relative. We will graft these standardized cultured cells into mouse 
muscle to obtain the FSHD humanized mouse model, thereby 
generating a well-controlled in vivo model for the study of FSHD. 
The very pressing issue in the field today is the verification of the 
current DUX4 model. The humanized mice produced will be used 
to investigate the hypothesis that DUX4 gene expression is a major 
cause of FSHD pathogenesis. In the obtained model, DUX4 expres-
sion will be evaluated during in vivo regeneration, and the conse-
quence of its expression on fiber turnover and satellite cell renewal . . . continued on next page
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system will allow better understanding of the action AOs, for evalu-
ating their potential suitability as a human therapy. We believe that 
this collaboration will give us new insights into a potential therapy 
for FSHD.
A FSH Society California Walk ’n’ Roll research fellowship grant
4.  Investigating mouse models of FshD
Paraskevi sakellariou, Ph.D./Robert J. Bloch, Ph.D.
university of Maryland school of Medicine, Baltimore, Maryland 
$40,000 over 1 year
summary: There is a great need for a valid mouse model for FSHD. 
Such an animal model would provide a valuable tool for explor-
ing the effects of newly cloned genes and novel proteins on the 
pathophysiology of this disease. It would also greatly facilitate 
research towards the development and testing of new therapeutic 
approaches to FSHD. We propose to examine two possible mouse 
models of FSHD, the FRG1 over-expressor, from Drs. Davide Ga-
bellini and Rossella Tupler, and mu-crystallin over-expressor, devel-
oped by Drs. Patrick Reed and Robert Bloch. I will breed these mice 
and test them for their physiological and morphological character-
istics, and their susceptibility to injury and ability to recover from 
injury. I will also initiate xenografting studies to create mice with 
humanized normal and FSHD ankle dorsiflexor muscles, combin-
ing methods that are routine in the Bloch laboratory with unique 
reagents provided by collaborators in the Wellstone Muscular 
Dystrophy Cooperative Research Center (MDCRC), “Biomarkers for 
Therapy of FSHD.”  These experiments should reveal the usefulness 
of available transgenic models for the study of FSHD, and promote 
the development of humanized mouse muscles for the study of the 
pathophysiology of FSHD in situ.
A FSH Society New York Festive Evening of Music research fellowship 
grant
5.  epigenetic abnormality in FshD
Weihua Zeng, Ph.D/Kyoko Yokomori, Ph.D.
university of california, Irvine, california 
$8,875 for 3-month extension
summary: Our preliminary findings indicate that D4Z4 repeat regions 
indeed interact with other genome regions, and that these interac-
tions are indeed disrupted in FSHD. With a three-month extension 
of my fellowship, I plan to perform a high-throughput identification 
of potential target genes that interact with D4Z4 using the recently 
developed “Chromatin Interaction Analysis using a Paired-End 
Tag” (ChIA-PET) technique. This strategy enables the genome-wide 
detection of chromatin interactions mediated by specific factors that 
are normally assembled at D4Z4. Identification of additional FSHD 
pathogenic genes other than FRG1 and DUX4 is important to explore 
future therapeutic targets to improve or prevent the clinical symp-
toms of FSHD.
FSH SOCiEtY GrANtS rECENtlY AWArDED
. . . from previous page
3.  Testing a therapeutic approach for FshD: evaluation of the efficacy of  
 AOs blocking DuX4 in a mouse model of isolated myofibres
Alexandra Tassin, Ph.D./Alexandra Belayew, Ph.D.
universite de Mons, Mons, Belgium
$15,000 over 1 year
summary: FSHD is considered the most frequent hereditary muscle 
disorder in adults, affecting one individual in 20,000. It is associ-
ated with contractions of the D4Z4 repeat array in the 4q35 sub-
telomeric region. In non-affected individuals, this array comprises 
11-100 tandem copies of the 3.3-kb D4Z4 element while in pa-
tients, only 1-10 D4Z4 copies are left (Wijmenga et al., 1992). Our 
group has identified the double homeobox 4 (DUX4) gene within 
each unit of the D4Z4 repeat array (Gabriels et al., 1999) and 
several studies have now demonstrated the causative role of DUX4 
in FSHD. We have demonstrate that the stable full-length DUX4 
messenger RNA (mRNA) is produced from the last D4Z4 unit in 
FSHD, using a polyadenylation signal in the flanking pLAM region, 
located telomeric to the distal repeat (Dixit et al., 2007) as recently 
confirmed by a study of genetic polymorphisms in hundreds of 
patients and thousands of non-affected individuals (Lemmers et al., 
2010). This polyadenylation site is necessary to develop FSHD on a 
contracted allele therefore called “permissive chromosome” (Lem-
mers et al., 2010). The mRNA from this distal D4Z4 unit contain 
the entire DUX4 open reading frame (ORF) and 1 or 2 alternatively 
spliced introns in the 3’UTR (DUX4-fl). In addition, a short DUX4 
mRNA terminates at the previously described polyadenylation site 
in the pLAM region but uses a cryptic splice donor site within the 
DUX4 ORF (DUX4-s). DUX4-fl was only detected in FSHD muscle 
cells and biopsies, whereas DUX4-s is detected both in control and 
some FSHD samples (Snider et al., 2010). A long DUX4 mRNA 
was detected in induced pluripotent stem cells (iPS cells) and hu-
man testis where the gene contains 4 additional exons and a more 
distal polyadenylation signal. Expression of this DUX4 mRNA was 
suppressed during differentiation of control iPS cells to embryoid 
bodies whereas expression of full length DUX4 mRNA persisted 
in differentiated FSHD iPS cells (Snider et al., 2010). These data, 
together with the conservation of the DUX4 ORF through evolu-
tion (Clapp et al., 2007) suggests a possible role of DUX4 in human 
development. 
 Dr. Tassin intends to undertake a post-doc for 3 months in 
2011 at King’s College London, to initiate a collaborative research 
project between our lab and that of Dr. P. Zammit. In agreement 
with Dr. Zammit, our collaborative project will consist of testing 
antisense oligonucleotides (AOs) directed against the 3’UTR of the 
DUX4 gene that we have developed in our laboratory, in collabora-
tion with Prof. S. Wilton (ANRI, University of Western Australia). 
These AOs have undergone preliminary screening in cell culture, 
but require more extensive testing. Dr. Zammit has developed 
mouse myofibre models that provide an ideal system to further test 
our AOs. The satellite cells associated with the isolated myofibres 
will be infected with retroviral vectors encoding DUX4, and the ef-
fects on myogenic progression and apoptosis of AO administration 
analysed. We want specially to focus on the pLAM region respon-
sible for the stabilisation of the DUX4 mRNA leading to FSHD. This 
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 Previously, with the support from the FSH Society in 2010, we 
found that a set of factors that normally assemble at D4Z4 repeats 
do not bind to these repeats in FSHD cells. Interestingly, these 
factors are known to function in gene silencing and long-distance 
genomic interactions, which appear to be particularly important 
for coordinated developmental gene regulation in human cells. Two 
candidate genes, FRG1 in a neighboring region and DUX4 encoded 
within D4Z4, have been identified whose artificial over expression 
did cause muscular dystrophy in vivo or a myoblast differentia-
tion defect in vitro, respectively. The loss of chromatin structure 
associated with gene silencing at D4Z4 may explain the abnormal 
expression of these genes in the disorder. However, FSHD patient 
muscle cells do not always over express these genes. Thus, there are 
likely to be additional unidentified genes and signaling pathways 
involved in the pathogenesis of FSHD. Our hypothesis is that D4Z4 
normally spreads a silencing effect to target genes through genomic 
interactions mediated by D4Z4-bound factors. This function is 
lost in FSHD, resulting in the abnormal over expression of a set of 
target genes that leads to clinical manifestations of the disorder. I 
am taking two strategies to test this model; (1) screen for any genes 
that might have lost factors similar to those that are lost from D4Z4 
in FSHD by high-throughput genome-wide chromatin immunopre-
cipitation (ChIP)-sequencing, and (2) directly search for genomic 
regions that interact with D4Z4 using biochemical chromatin con-
formation capture (3C)-related methods. Any candidate genes iden-
tified by these assays will be tested for their effect on cell viability, 
proliferation/differentiation, and muscle-related downstream gene 
expression. I will try to re-create the expression change detected 
in FSHD cells in normal human myoblasts (by over expression or 
repression) and compare it to the phenotypes of FSHD myoblasts 
to determine whether the candidate gene contributes to the FSHD 
cellular phenotype. My research aims to decipher the epigenetic 
abnormality mechanism in FSHD, which should provide novel in-
sight into the disease mechanism and thus potentially present new 
therapeutic strategies. 
A FSH Society Sanford Batkin & Helen Younger and David Younger 
research fellowship grant 
6.  Analysis of DuX4-fl expression
Peter L. Jones, Ph.D.
Boston Biomedical Research Institute, Watertown, Massachusetts
$7,500 for 1 year
summary: We request support from the FSH Society for our pilot 
project investigating DUX4 expression in unaffected and FSHD 
subjects. The DUX4-fl expression model for FSHD has not been 
independently validated, likely due to the lack of quality clinical re-
sources in the field. At this point in FSHD research, validating and 
expanding upon the DUX4-cytotxicity model for pathogenesis is 
vital to the entire field and we are best positioned to do the neces-
sary experiments with the unique set of highly controlled reagents 
being generated by the NIH Wellstone Muscular Dystrophy CRC for 
FSHD at BBRI. Each Wellstone cohort consists of an FSHD affected 
subject and an unaffected first-degree relative. Each subject donated 
two biopsies, one from the biceps and one from the deltoid. A por-
tion of each biopsy was used to derive myogenic cell cultures. Quite 
surprisingly, in our initial preliminary results using 4 cohorts we 
found some inconsistencies with the published DUX4 expression 
results that have warranted further investigation. Therefore we have 
begun a much larger effort to analyze DUX4-fl mRNA and protein 
expression in a larger set of Wellstone cohorts using RT-PCR and 
immunostaining (ICC). However, this project is not funded at all 
in my lab or in the original Wellstone budget and my lab receives 
no financial support from the Wellstone Center. The Wellstone has 
supported us by providing us with cells, which we culture, and 
RNA which the Louis Kunkel lab purified from biopsies (we do 
not actually work with the biopsies) and we have been fortunate to 
receive these Wellstone samples. At this point, to ensure that our 
results are statistically meaningful, we need to analyze many more 
cells and biopsy RNAs and it has become cost prohibitive. There-
fore I am requesting financial support for consumables and services 
(DNA sequencing) to conduct these experiments.
A FSH Society Cape Cod Walk ’n’ Roll fellowship research fellowship 
grant
August 2010 round
 
1. small Molecule screen to Identify Inhibitors of DuX4-mediated Toxicity,  
 Therapeutic Approach for FshD
Darko Bosnakovski, D.V.M., Ph.D.
university “Goce Delcev” stip
Faculty of Medical sciences
stip, R. Macedonia
$90,000 over 2 years
summary (Provided by Applicant): The goal of this proposal is to discov-
er a chemical compound that efficiently inactivates the DUX4 protein 
and to work towards a drug for a therapeutic approach to FSHD. The 
aims of the proposed study targets the most crucial topic and urgent 
needs of FSHD patients: specific and direct pharmacological therapy. 
First, the project help to narrow focus from 82 potential compounds 
to inactivate DUX4, implicated as necessary to cause FSHD, as a re-
sult of high-throughput screening to the most promising direct DUX4 
inhibitors. Second, scientists will evaluate effectiveness of DUX4 
inhibition and study the properties of the selected compounds.
A FSH Society New York Festive Evening of Music research fellowship 
grant
 
2.  Defining the Tissue and cell specificity of the human DuX4 promoter  
 in Mice
scott harper, Ph.D.
The Research Institute at Nationwide children’s hospital,  
columbus, Ohio
$50,000 over 1 year
t
. . . continued on next page
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type mapping of patients and unaffected individuals with D4Z4 
contractions. Their findings provide evidence that the disease 
develops in individuals who have BOTH a D4Z4 repeat contrac-
tion AND a specific sequence in the pLAM domain at the 3’ end 
of the D4Z4 array (Figure 1). The D4Z4 repeat contraction results 
in “relaxed chromatin”, and allows the transcription of the DUX4 
gene in the final D4Z4 repeat. However, it is the sequence in the 
pLAM domain that creates a site that is recognized by the cellular 
machinery allowing cleavage of the mRNA and the addition of a 
poly(A) tail. Without a poly(A) tail in the 3’ untranslated region 
(3’ UTR), transcripts are rapidly degraded and never translated 
into proteins. With these tails, transcripts are stabilized and ap-
propriately localized in the cell, allowing for protein translation. 
In individuals who have D4Z4 contractions but a single base 
change in the distal sequence, the cell does not recognized it as 
a “polyadenylation signal” (PAS) site, no poly(A) tail is added to 
the 3’UTR of the transcript, the DUX4 transcript is unstable, no 
DUX4 protein is made, and the individuals are protected from 
getting the disease. Within this cascade are several opportunities, 
at least theoretically, to treat or even prevent FSHD in susceptible 
individuals. Any intervention that prevents the addition of the 
poly(A) tail to the DUX4 transcript is a potential therapeutic ap-
proach for FSHD.
 The research project aims for a direct line to a novel therapeutic 
approach. The toxicity leading to FSHD depends of effective mRNA 
processing in which the DUX4 transcript is cleaved and modified 
by the addition of a poly(A) tail. If one of these processes could 
be blocked, then the mRNA would be destabilized and the FSHD 
genotype would yield a normal phenotype. Clearly, it is untenable 
to interfere with mRNA processing in general because of the toxicity 
to the cell. Therefore, understanding the mechanisms by which a 
cell can bypass a specific PAS site would suggest a mechanism for 
selectively blocking the PAS site in the pLAM domain in the DUX4 
gene without generally affecting cellular mRNA processing. This 
would be an effective treatment for patients with FSHD.
A FSH Society William R. Lewis, Sr., M.D. and Family research 
fellowship grant
Dr. thomas rando describes the genetic determinants of FSHD leading to 
expression of DUX4
summary: Since animal models, particularly mice, are crucial tools 
for studying disease pathogenesis and developing potential thera-
peutics, the absence of an FSHD mouse model is a fundamental 
problem in the FSHD field. A major goal of the Harper lab is to 
generate an FSHD mouse model expressing a single FSHD-permis-
sive human D4Z4 repeat, and to use this model to understand the 
role of the D4Z4-resident gene, DUX4, in FSHD pathogenesis, and 
develop RNAi therapeutics targeting DUX4. This project will care-
fully define the developmental and cell specific expression patterns 
of DUX4p-GFP mice, and develop an AAV vector to determine 
whether a viral-mediated vascular delivery approach can produce 
the same expression patterns. These studies are important first steps 
toward developing an AAV-mediated D4Z4 mouse model.tic agents.
 
A FSH Society Jacobs Family and Friends, California Walk ’n’ Roll, 
and Kelly Family and Friends research fellowship grant
 
3.  Identification of a Novel FshD Biomarker [an unknown 50 kDa  
 polypeptide highly expressed in FshD samples]
Jessica sun, Ph.D./Peter Jones, Ph.D.
Boston Biomedical Research Institute, Watertown, Massachusetts
Partial funding for preliminary data $10,000 over 1 year
summary: Screening FSHD patient-derived myoblasts, control 
myoblast, and muscle samples for expression changes at the 
proteomic level produced an unknown 50 kDa polypeptide highly 
expressed in FSHD samples compared to controls. Interestingly, 
this polypeptide is equally expressed in both normal and FSHD-
patient derived myoblasts and early myotubes, however, unlike 
in control cells where its expression decreases, this unknown 
polypeptide remains highly expressed in differentiated muscle 
suggesting it is developmentally regulated and this regulation is 
disrupted in FSHD. Identifying this protein will provide insight 
into FSHD pathophysiology, will be a useful FSHD biomarker, and 
may be one of the first proteins consistently and specifically up 
regulated in viable FSHD muscle. Therefore, generating specific 
and standardized antibodies to this protein will provide a useful 
resource for clinicians and basic FSHD researchers.
A FSH Society Cape Cod Walk ’n’ Roll research fellowship grant
4.  Toward Therapeutics for FshD: understanding mRNA Processing
Thomas A. Rando, M.D., Ph.D./Antoine de Morree, Ph.D.
Department of Neurology and Neurological sciences
stanford university sch ool of Medicine, Palo Alto, california
$200,000 over 2 years
This research project is being matched dollar for dollar up to 
$100,000 by the stanford Office of Medical Development and 
Dr. Gary steinberg, stanford Institute for Neuro-Innovation and 
Translational Medicine (sINTN).
summary: Recently, the group of Dr. van der Maarel reported in 
the journal Science their findings of the high resolution haplo-
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5.  A multicenter collaborative study on the clinical features, expression  
 profiling, and quality of life of pediatric FshD
Jean Mah, M.D.
Alberta children’s hospital, calgary, Alberta, canada
us$96,669 over 2 years, Year 1 us$51,434 & Year 2 us$45,235
Project is being co-funded by the FshD Fund Muscular Dystrophy 
canada FshD Fund at cDN$65,000.
summary: FSHD is one of the most common types of muscular dys-
trophy. Despite recent advances in the understanding of the molecu-
lar genetics of FSHD, the exact mechanism responsible for the disease 
remains unknown, and presently there is no cure. As well, the preva-
lence, clinical variability, cross cultural presentation, and the psycho-
ongoing or completed fsh society research fellowship grants since last research newslettert
Genome-wide analysis of FRG1-mediated splicing defects in 
FSHD and iFSHD 
Yi Xing, Ph.D.
The university of Iowa, Iowa city, Iowa
$39,998 over one year
A FSH Society Aubrie Lee Family Research Grant for Infantile FSHD & Fire 
Island & Fabiola Bertinotii research fellowship grant
A ncRNA regulating the epigenetic switch at the basis of FSHD 
Daphne cabianca, M.s./Davide Gabellini, Ph.D.
Division of Regenerative Medicine, centro san Raffaele del Monte, 
Milano, Italy
$45,000 over eighteen months 
A FSH Society New York Festival of Music research fellowship grant
Molecular mechanisms involved in FSHD
Julie Dumonceaux, Ph.D./Gillian Butler Browne, Ph.D.
Association Institut de Myologie, Paris, France
$37,800 over one year
A FSH Society Grant Delta Railroad Construction Company research 
fellowship grant
Exploring the interplay between the nuclear envelope and the 
higher order chromatin organization of the D4Z4 array in control 
and FSHD cells
Frédérique Magdinier, Ph.D.
Laboratory INseRM uMR 910 Medical Genetics & Functional Genomics, 
Faculté de médecine de la Timone, Marseille, France
$30,000 over one year
A FSH Society Family Picnic research fellowship grant
FSHD iPS cells: bioinformatics support
Michael Kyba, Ph.D.
Minnesota Medical Foundation, university of Minnesota, Minneapolis, MN
$45,000 over one year
A FSH Society New York Festival of Music research fellowship grant
The Boston Biomedical Research Institute Senator Paul D. 
Wellstone Muscular Dystrophy Cooperative Research Center for 
FSHD, Project 4 – Mouse Model Studies for FSHD Biomarkers
Jeffery Boone Miller, Ph.D.
Boston Biomedical Research Institute, Watertown, Massachusetts
NIh sen. Paul Wellstone MD cRc for FshD
& Robert J. Bloch, Ph.D./Patrick Reed, Ph.D.
university of Maryland school of Medicine, Baltimore, Maryland
NIh sen. Paul Wellstone MD cRc for FshD
$160,000 over four years
A FSH Society Stuart Lai Mouse Model Development research fellowship 
grant
Analyses of functional domains in the pro-apoptotic protein 
DUX4
Alberto Luis Rosa, M.D., Ph.D.
INIMec-cONIceT, National Research council of Argentina 
Laboratorio de Biologia celular y Molecular, cordoba, Argentina
$59,040 over two years
A FSH Society Marjorie and Gerald Bronfman research fellowship grant
Investigating DUX4 Structure and Function Using Rational 
Mutagenesis
scott Q. harper, Ph.D.
The Research Institute at Nationwide children’s hospital, columbus, Ohio 
$40,000 over one year
A FSH Society Jacobs Family and Friends research fellowship grant 
social impact of FSHD on affected individuals constitute a significant 
public health concern. Emerging therapeutic trials will benefit from 
the availability of natural history data and reliable outcome measures 
for both children and adults with FSHD. The main objectives of this 
study are: 1) to establish a standardized muscle testing protocol for 
use in children and youth with FSHD; 2) to describe the clinical 
phenotypes of pediatric onset FSHD; 3) to evaluate the impact of 
FSHD on health-related quality of life and disability across different 
age groups; and 4) to explore potential genetic modifiers of clini cal 
phenotypes and disease progression in FSHD.
A FSH Society New York Festive Evening of Music research fellowship 
grant FSH Watch
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FSHD does not yet have a cure. One area open to research is a careful analysis of the multiple muscles that are affected in 
FSHD. To obtain a sufficient number and size of samples, these 
specimens are collected immediately after someone with FSHD 
dies.   Tissue donation is recognized as a magnanimous act by 
all major religions. However, the decision to donate is a very 
personal one. No one answer is appropriate for all. But for those 
individuals and families that make this decision to donate tissue, 
a procedure is available by which you can leave a legacy for FSHD 
research.
 The National Institutes of Child Health and Human Develop-
ment (NICHD) funded the NICHD Brain and Tissue Bank at the 
University of Maryland to work with families who have made the 
decision to donate tissue following the death of the affected indi-
vidual. The decision should be made with the active participation 
of the individual with FSHD. Equally important, the legal next of 
kin has to actively participate and agree to the decision. This is 
critical because once the Bank is informed of the death of the do-
nor, the next of kin has to give final consent for tissue donation. 
In fact, it is most beneficial if both the donor and the next of kin 
sign the consent form.
 To initiate the process of donation a donor may pre-register 
with the Bank via the internet at www.btbankfamily.org or by call-
ing the Bank at 800-847-1539 to request a registration packet. 
This is also the time to ask questions. After the registration is 
complete, it is important to keep the Bank informed when the 
health of the potential donor changes. Since the quality of the 
tissue, and therefore its potential for important FSHD research, 
deteriorates with time after death, it is important to contact the 
Bank within hours after death has occurred. Ideally the tissue has 
to be recovered within 24 hours after death. If it hasn’t been done 
already, the family has to provide the Bank with contact informa-
tion for the funeral home selected by the family as well as the 
names of local hospitals in which the donor received care. The lat-
ter is important because most hospitals will not assist in the tissue 
donation if the donor was not seen at that hospital. If the donor 
rather than the next of kin signed the consent form, then the next 
of kin has to sign a new form. The consent form can be processed 
via e-mail or fax. It is vital that the consent form be completed 
and returned as soon as possible because the Bank cannot contact 
a pathologist until the completed form is returned. The tissue 
recovery from a FSHD donor is more complex than for most tis-
sue donations. The Bank has to recruit a pathologist willing and 
capable of recovering the various muscles. There is no cost to the 
family for the tissue donation. Tissue donation is completely com-
patible with an open viewing. 
 The Brain and Tissue Bank for Developmental Disorders at the 
University of Maryland in Baltimore is a tissue resource estab-
lished to further research aimed at improved understanding, care 
and treatment of developmental disorders. The Brain and Tissue 
Bank serves as an intermediary between people who wish to have 
tissue donated for research upon the time of their death and the 
researchers who need this tissue for their vital work (www.btbank.
org). Tissues listed on file at the BTB to be collected are deltoid, 
gastrocnemius, wrist flexors flexor carpi radialis, flexor digitorium 
superficialis), vastus lateralis, vastus medialis, hamstrings, upper 
trapezius, biceps, triceps, tibialis anterior, rhomboids, lower tra-
pezius, retina, cochlea, and brain motor cortex). 
Tissue Donation for Research 
Become a registered FSHD tissue donor 
     R e s e a R C h  s t U d i e s
by h. ROnald ZielKe, Ph.d
The Eunice Kennedy Shriver NICHD Brain and Tissue Bank for Developmental Disorders
University of Maryland, Baltimore, Maryland, USA
understanding how d4Z4 chromatin is altered in fshdt
FSHD is one of the most prevalent muscular dystrophies. 
The majority of FSHD cases are linked to a decreased 
copy number of D4Z4 macro-satellite repeats at the sub-
telomeric region of chromosome 4q (FSHD1). A much 
smaller number of FSHD cases have no repeat contrac-
tion (FSHD2). Understanding the molecular pathway of a 
disease is important for the development of mechanism-based treatments. 
Despite the recent breakthrough discovery of the critical link of FSHD to the 
de-repression of the DUX4 gene, the molecular mechanism of FSHD is still 
not completely understood. With the generous support of the David and 
Helen Younger Research Fellowship from the FSH Society, we previously 
found that the D4Z4 repeat cluster normally contains a “heterochromatin” 
by WeihUa ZenG, Ph.d. 
University of California, Irvine, California
structure specific for repressing gene expression, and that this structure is 
lost in FSHD patient cells. We reported that histone H3 lysine 9 tri-methylation 
(H3K9me3) is specifically lost from D4Z4 in FSHD patient cells (but not in other 
tested muscular dystrophy cells). This epigenetic change was observed even in 
patient peripheral blood-derived lymphoblasts, making it potentially useful as 
a diagnostic marker. Importantly, this histone methylation loss is observed in 
both FSHD1 and FSHD2, and is more FSHD-specific than (and distinct from) the 
previously identified DNA hypomethylation. 
 We also identified several factors in this pathway, including the histone 
methyl transferase responsible for H3K9me3 at D4Z4 (i.e. SUV39H1) as well as 
the downstream targets HP1-gamma and cohesin, which work together to form 
transcriptionally repressive heterochromatin. While no apparent mutation or 
abnormality was observed in SUV39H1 in FSHD, HP1-gamma and cohesin bind-
ing to D4Z4, which is dependent on H3K9me3, is lost in FSHD. Interestingly, the 
binding of these two effectors is cell type-specific, suggesting their role in cell 
Weihua Zeng, Ph.D. 
FSH Watch
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Development of a Mouse Xenograft Model for FSHD    
Updates from recently funded FSH Society grantees
by ChaRis hiMeda, Ph.d., and MaRietta BaRRO, Ph.d.
Boston Biomedical Research Institute (BBRI), Watertown, Massachusetts
The Senator Paul D. Wellstone Muscular Dys-trophy Cooperative Research Center for FSHD 
Research, which is funded by the National Institutes 
of Health and based at Boston Biomedical Research 
Institute (BBRI), focuses its research efforts on de-
veloping therapeutic strategies for the treatment of 
FSHD. A current focus of the Wellstone Center is the 
development of a mouse model to study the charac-
teristics of FSHD muscle cells in the context of a live 
animal. This project is being conducted in the lab of 
Center Director Dr. Charles Emerson, and is led by 
Dr. Marietta Barro and Daniel Zuch with the help of 
Dr. Jennifer Chen and Dr. Kathryn Wagner. 
 FSHD is genetically linked to the loss of repeti-
tive DNA sequences on chromosome 4. Although 
this genetic defect was identified over 20 years ago, 
the molecular basis of the disease is still unknown. 
Because they reproduce disease mechanisms in the complex environ-
ment of a mammalian body, animal models are an invaluable aid to 
understanding the nature of human disorders and testing potential 
therapies. However, since the specific causative gene(s) linked to 
FSHD have not yet been identified, there is currently no established 
animal model of the disease. 
 To provide such a valuable tool, Dr. Barro and colleagues are 
developing a “humanized” mouse model by engrafting muscle stem 
cells from FSHD patients and their unaffected relatives into the 
muscles of live mice. Following engraftment, normal human muscle 
stem cells are able to form fibers in the host mouse that persist for 
months after transplantation. It is expected that transplanted FSHD 
muscle cells will display disease characteristics, allowing Wellstone 
investigators to study the development of the dis-
ease in the context of a live animal. Recent evidence 
implicates the DUX4 gene as a strong candidate for 
FSHD, and the humanized mouse model will be 
used to investigate the hypothesis that inappropri-
ate expression of DUX4 is a major cause of FSHD 
pathogenesis. Expression of the DUX4 gene will be 
evaluated during real-time muscle regeneration in 
live animals, and the consequences on muscle fiber 
maintenance and muscle stem cell renewal will be 
assessed.
       The success of this project depends largely on 
the FSHD repository developed by the Wellstone 
Center, a collection of muscle biopsies and derived 
muscle cells from FSHD patients and their unaffect-
ed relatives. This repository, which represents the 
most comprehensive and well-controlled collection 
of FSHD patient samples in the world, is coordinated by Dr. Wag-
ner, Dr. Genila Bibat, Dr. Emerson, and Dr. Chen, and maintained 
at BBRI with technical assistance from Kendal Hanger. It allows 
researchers unique access to fresh muscle stem cells from cohorts of 
FSHD patients and their appropriate controls, i.e., first-degree family 
members. The Wellstone repository also provides an unprecedented 
opportunity to correlate FSHD progression with muscle biomark-
ers. As the genetic basis of this inherited disorder is just beginning 
to be elucidated, both the Wellstone repository and tools such as the 
humanized mouse model are helping researchers study the disease 
from a more clinically relevant vantage point and test novel inter-
vention strategies designed to improve the quality of life for FSHD 
patients. FSH Watch
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type-specific chromatin organization that is likely involved in the tissue-specific 
clinical manifestations of the disease.
 Additional D4Z4 homologs are known to exist near centromeres on mul-
tiple chromosomes, but they are largely uncharacterized and their relationship 
to 4q D4Z4 was undetermined. Our more recent study revealed that unlike 
D4Z4 on chromosomes 4q (and 10q), there are high degrees of nucleotide 
variation in D4Z4 homologs on other chromosomes that frequently disrupt 
their DUX4 open reading frames (ORF). Although heterochromatin marks are 
also present on these homologs in normal cells, they remain unchanged in 
both FSHD1 and FSHD2 cells. The results indicate that the specific preserva-
tion of the DUX4 ORF and the unique epigenetic alterations are restricted to 
4q and 10q D4Z4 repeat clusters, further highlighting their critical role in FSHD 
pathogenesis.
 Based on these findings, we hypothesize that HP1-gamma and cohesin 
play a pivotal role in exerting a repressive effect at D4Z4. Over expression of 
DUX4 within the D4Z4 repeat may also be explained by the loss of 
these heterochromatin marks. Recent studies indeed confirmed 
the critical role of cohesin in developmental gene regulation, further 
supporting our model and the significance of its loss at D4Z4 in 
FSHD. We are trying to understand how D4Z4 chromatin is altered in 
the two genetically distinct types of FSHD. Furthermore, it remains 
unclear how exactly DUX4 de-repression occurs, how it leads to the 
development of disease, and whether there are other genes that 
contribute to the disease phenotype. Active collaboration among 
FSHD researchers in the field will be essential for solving the myster-
ies of FSHD pathogenesis. Our common goal is to apply our research 
results to the design of effective therapeutic methods in the near 
future.
 Work is made possible by a FSH Society Sanford Batkin & Helen 
Younger and David Younger research fellowship grant 
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The NIH-funded Wellstone Muscular Dys-trophy Cooperative Research Center for 
FSHD headquartered at Boston Biomedical 
Research Institute, Watertown, Massachusetts 
reports:
1. on the establishment of an unique cell reposi-
tory of  mortal and immortalized FshD and 
control muscle cell lines from more than 60 
individuals over 30 families, lead by Drs. Kath-
ryn Wagner of Kennedy Krieger Institute, 
Baltimore, Maryland and Charles Emerson 
and Jennifer Chen at BBRI. Cells from eight 
family cohorts are now available for distribu-
tion worldwide to FSHD researchers. To find 
out how to obtain FSHD and control primary 
skeletal muscle cell strains and immortalized 
clonal cell lines for research please see http://
wellstone.bbri.org. These cell lines are a 
unique resource to identify disease biomark-
ers for FSHD to better understand the pathology of FSHD and to 
monitor efficacy of drugs in future FSHD clinical trials, to develop 
cell models for drug screens to develop therapeutics for FSHD, 
and to generate humanized mouse models of FSHD for studies of 
disease pathology and drug testing (see accompanying article by 
Drs. Barro and Himeda).
2. on identification of biomarkers of myostatin inhibition, lead by 
Drs. Kathryn Wagner at KKI and Louis Kunkel at Children’s 
Hospital, Boston, in collaboration with Acceleron Pharma. 
Myostatin is a natural regulator of muscle growth and leading 
drug target ffor improving muscle strength in patients with 
FSHD and other muscular dystrophies. The Wellstone study, 
published in Physiological Genomics ON January 25, 2011 
[2011 Apr 27;43(8):398-407] “Gene expression profiling of 
skeletal muscles treated with a soluble activin type IIB recep-
tor,” investigated Acceleron’s anti-myotatin drug, ACE-031 
in mice utilizing genome-wide RNA expression array. Their 
findings identify a unique set of  RNA biomarkers expressed in 
muscle in animals treated with drug. These biomarkers will be 
invaluable tools, providing a molecular signature for clinicians 
to conduct clinical trials to monitor the activities of anti-myo-
statin drugs from Acceleron and other pharmaceutical compa-
nies,  enabling researchers to quickly evaluate whether patients 
with different muscular dystrophies including FSHD respond 
positively to drug treatment.
3. that Drs. Robert Bloch, university of Maryland, Baltimore, Mary-
land, and Jeffrey Boone Miller have developed a line of transgenic 
mice that express mu-crystallin specifically in skeletal muscle. 
They are breeding the mice in a mixed genetic background with 
each other, and are continuing to do so to characterize their 
muscles, physiologically and morphologically. They are also that 
have been used as possible models of FSHD.
So far, they have only had a sufficient number of heterozygotes 
(mice that carry the transgene for mu-crystallin on only one of their 
chromosomes) to study, in the mixed genetic background. The 
heterozygotes have a phenotype, i.e., they are different from normal 
mice. In particular, the diameter of the muscle fibers in the tibialis an-
terior (TA) muscle is decreased, more of the fibers show evidence of 
increased degeneration and regeneration, and the muscles are weaker. 
Overall, these results suggest that the transgenic mice have muscle 
pathology, but it is still not clear if the pathology mimics that seen 
in FSHD. They must still examine the homozygotes (mice that carry 
the transgene on two chromosomes), which should express twice the 
amount of mu-crystallin. They hope to be able to begin these experi-
ments soon and expect to observe more pronounced changes in these 
mice than in the heterozygotes.
 They are of course hoping that the mice reproduce some of 
the key features of FSHD. If so, they will use them to begin to 
test some of the therapeutic approaches suggested for the treat-
ment of the disease (e.g., myostatin inhibitors), in collaboration 
with members of the Wellstone Center. They will also use them to 
study the pathogenic process. Having additional strains of mice 
would be important for either plan to move forward. If we find 
that the mice we are already studying show FSHD-like pathology, 
they will go through another round of transgenesis to obtain ad-
ditional strains with different levels of mu-crystallin.
 Work made possible by a FSH Society Stuart Lai Mouse Model 
Development fellowship grant.
NIH BBRI Wellstone MD CRC for FSHD notes recent accomplishments 
Developing biomarkers for therapy of FSHD
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FSH SOCIETY: Organization & Mission
       n e W s  a n d  e V e n t s
DO YOU FOllOW 
tHE SOCiEtY’S 
FACEBOOk AND 
YAHOO! GrOUPS 
PAGES?  
Go to www.facebook.com and sign up. It is 
free and easy. search on Fsh society and 
join the discussion. You can also join Fsh 
society Yahoo! Groups forum, online since 
the 1990’s and with tens of thousands of 
searchable posts. Bookmark them and 
come back often. You can also access the 
Fsh society FaceBook page and Yahoo! 
Groups by going to www.fshsociety.org 
clicking on the “community & Reference” 
menu tab at top of page and then selecting 
“Online community” in the left hand 
vertical navigation menu.
HAvE YOU MADE A GiFt tO tHE 
SOCiEtY iN 2011?
Please help now. The Fsh society is a 
world leader in combating muscular 
dystrophy. It has provided over three 
million dollars in seed grants for pioneering 
research worldwide and has developed 
an international collaborative network of 
patients and researchers. If you are not 
already a member, won’t you join in this 
effort?  Please return your membership gift, 
or another gift, in the enclosed envelope. Or 
contribute online at www.fshsociety.org. Go 
to contribute, and select the gift category 
you wish to make. Thank you.
COMBiNED FEDErAl CAMPAiGN 
(CFC), 2011 CAMPAiGN
The Fsh society has been approved by 
the Office of Personnel Management 
for the 2011 campaign. The cFc is the 
world’s largest and most successful annual 
workplace charity campaign, with more 
than 300 cFc campaigns throughout the 
country and internationally to help to raise 
millions of dollars each year. Pledges made 
by Federal civilian, postal and military 
donors during the campaign season 
(september 1st to December 15th) support 
eligible non-profit organizations that 
provide health and human service benefits 
throughout the world. The Fsh society’s 
identification number is 10239.
FSH SOCiEtY rECEivES CHAritY NAviGAtOr’S HiGHESt 4-StAr rAtiNG     
The Fsh society has earned charity Navigator’s “third consecutive 4-star rating 
for its ability to efficiently manage and grow its finances. Only 13% of the charities 
we [charity Navigator] rate have received at least 3 consecutive 4-star evaluations, 
indicating that Fsh society consistently executes its mission in a fiscally 
responsible way, and outperforms most other charities in America. According 
to charity Navigator, “This ‘exceptional’ designation from charity Navigator 
differentiates Fsh society from its peers and demonstrates to the public it is 
worthy of their trust.”  see http://www.charitynavigator.org  or www.fshsociety.org for direct link.
The FSH Society is a 501(c)(3) non-profit tax-exempt U.S. corporation organized in 1991 to fund, encourage and promote scientific and clinical research on FSHD. The FSH Society is 
a world leader in combating muscular dystrophy. It has provided three million dollars in seed 
grants to pioneering research worldwide and it has created an international collaborative network 
of patients and researchers. The Society relies entirely on private grants and donations.
 FSHD is a most prevalent muscular dystrophy. FSHD affects men, women and children. It 
occurs with a frequency of 1/14,000 in the population and may be higher due to misdiagnosed 
cases. The majority of cases of FSHD are caused by a genetic defect or deletion on chromosome 
4. FSHD is genetically autosomal dominant meaning that a child of either sex has a fifty percent 
chance of inheriting the genetic defect from an affected parent. Thirty percent of new FSHD pa-
tients have no prior family history and are a result of a congenital spontaneous genetic mutation. 
Once present, FSHD is genetically transmissible. Genetic diagnostic and prenatal diagnostic tests 
are available as well as pre-implantation genetic diagnosis (PGD).
 FSHD causes a progressive loss of all skeletal muscle, with weakness usually noticeable start-
ing with facial, scapular/back and upper arm muscles and progressing to all skeletal muscles. 
The prognosis includes both a loss of muscular strength that limits personal and occupational 
activities of most FSHD individuals and a loss of mobility in perhaps twenty percent of the cases. 
The early facial involvement is a hallmark of FSHD. The age of onset is variable as is the eventual 
extent and degree of muscle loss, but noticeable muscle weaknesses are usually present by the 
age of twenty in ninety-five percent of patients. Hearing loss and retinal abnormalities associated 
with FSHD have been reported, but the frequency of these effects and their relationship, if any, to 
the causative gene for the muscle defect are uncertain.
The Fsh society was created because of a need for a comprehensive resource for FshD individuals 
and families. Purposes of the organization are:
n to encourage and promote scientific and clinical research and development on the causes, 
alleviation of suffering, treatment and cure of FshD;
n to support such research and development through solicitation of grants and contributions from 
individuals, private foundations, the pharmaceutical industry and others to support such research 
and development;
n to make grants and awards to qualified applicants so that such applicants may accomplish such 
research and development;
n to accumulate, disseminate and encourage the exchange of information about FshD, including edu-
cating the general public, relevant governmental bodies, and the medical and scientific professions 
about the existence, diagnosis and treatment of FshD;
n to actively cooperate with related organizations and foster communication among all interested 
parties;
n to serve as a resource for individuals and families with FshD, represent them and advocate on  
their behalf.
The Society invites contact from any interested individuals, families, physicians, caregivers, chari-
table organizations, government agencies, industry, scientific researchers and academic institutions. 
Any inquiries regarding membership, charitable donations, purposes and goals or other issues 
pertaining to the Society and FSHD, should be addressed to the FSH Society Watertown office.
t
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systems. It becomes even more important to have a solid model 
and dataset to test.
9.  Epigenetics/genetics. There is the need to further evaluate 
FSHD1, FSHD2 and phenocopies using the genetic approach. 
Resolve and establish genes involved in the pathophysiology of 
FSHD (DUX4, FRG1, FRG2 and other 4q35 loci, PitX1, Pax3, 
Pax7 and other impacted distributed loci, related cascades and 
pathways, etc.)
10.  Clinical trials readiness. There is a need to revisit what we know 
about the pathological progression of FSHD. 
Learn more about the group at:  http://www.fshsociety.org/assets/pdf/
IRCWorkshop2010WorkingConsensusOfPrioritiesGalley.pdf. 
iNtErNAtiONAl FSH CONSOrtiUM OUtliNES 
rESEArCH PriOritiES FOr FSHD
. . . from page 5
sh1FRG1 doses ….
 “In conclusion, we have shown that we can prevent disease 
progression with systemic, AAV6-mediated FRG1 RNAi performed 
following disease onset. This work exemplifies the power and 
specificity of RNAi in a widespread tissue in a living animal and 
offers a potential route to clinical application and treatment for 
individuals who are already showing symptoms of disease. The 
efficient, stable, long-term therapeutic reduction of pathological 
signs in the FRG1 mouse suggests the added potential clinical ben-
efit of efficacy with limited dosing. This therapy allowed significant 
improvement of disease and could potentially be translated to hu-
man patients. The knowledge gained through these studies could 
facilitate the development of new therapies to treat FSHD and 
other diseases.”
A POSSiBlE APPrOACH FOr trEAtiNG FSHD 
WitH rNAi tHErAPEUtiCS
. . . from page 9
fshd international research Consortium 
meeting is scheduled 
t
The FSH Society FSHD International Research Consortium 
workshop will be held on Monday and Tuesday, November 
7-8, 2011, at the Boston Biomedical Research Institute (BBRI), 
in Watertown, Massachusetts. Silvère van der Maarel, Ph.D. 
(Leiden University Medical Center and Fields Center for FSHD, 
Leiden, Netherlands) and Robert H. Brown, Jr., M.D., D.Phil. (The 
University of Massachusetts, Worcester, Massachusetts, USA) will 
be the scientific and clinical co-Chairs respectively, and Daniel 
Perez (FSH Society) will serve as scientific/organizational chair. 
Dr. Charles Emerson, Jr., Director, of BBRI and co-Director of the 
NIH NICHD BBRI Sen. Paul D. Wellstone Muscular Dystrophy 
Cooperative Research Center for FSHD, has graciously offered to 
host the meeting at the headquarters of BBRI.
 Monday will be a full day of research presentations and 
discussions and Tuesday will be a half day of research planning. 
The Society annually organizes, sponsors, and funds this meeting. 
There are no registration fees for professionals working on FSHD. 
Other co-sponsors to date are NIH NICHD BBRI Sen. Paul D. 
Wellstone Muscular Dystrophy Cooperative Research Center for 
FSHD. This will be an important time for the expected 100 FSHD 
research and clinical community to convene and network.
FSHD researchers, clinicians, patients and funding agencies gather from 
around the world to discuss the latest developments in FSHD at the 2010 FSH 
Society research workshop
FSH WatchFSH Watch
Centers for Disease Control [CDC].
 For more information on the MDCC plans, staff, rosters, meet-
ing agendas and  minutes please go to www.fshsociety.org click on 
Research tab at top, then click on FSHD Research Plans/U.S. NIH 
MDCC in left hand navigation or see http://www.fshsociety.org/pages/
resPNIHMDCC.html. 
FSHD ADvOCACY EFFOrtS ON tHE U.S. PrESiDENt’S 
MUSCUlAr DYStrOPHY COOrDiNAtiNG COMMittEE
. . . from page 7 
FSH Watch
CrEAtiNG A MUltiCENtEr COllABOrAtivE 
StUDY ON tHE CliNiCAl FEAtUrES, EXPrESSiON 
PrOFiliNG, AND qUAlitY OF liFE OF iNFANtilE 
ONSEt FSHD
. . . from page 12
 Utilization of the Cooperative International Neuromuscular 
Research Group (CINRG) study sites will provide an ideal network 
of dedicated researchers to study the clinical features of infantile 
onset FSHD. In addition, collaboration with local and international 
experts in the fields of pediatric ophthalmology, audiology, speech, 
and neuropsychology is included in the study plan to help define 
and raise awareness about the extra-neuromuscular manifestations 
of infantile FSHD. The success of this single visit cross-sectional 
study will generate data to lay the groundwork to establish a larger 
prospective cohort for determination of the natural history of FSHD 
and the clinical outcome parameters for potential therapeutic trials. 
 To fulfill the above study objectives, 50 participants with infantile 
onset FSHD will need to be recruited from participating CINRG sites 
across the Unites States as well as other centers in Canada, Europe, 
Japan, and Australia. The participants may be adults or children 
having a confirmed diagnosis of infantile onset FSHD.  If you would 
like more information about the infantile FSHD study and/or to find 
the nearest CINRG participating sites, please contact Robert Casper, 
Study Project Manager (RCasper@cnmcresearch.org) or visit the CINRG 
website at www.cinrgresearch.org for further information. FSH Watch
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and Jane Hewitt, believed that something 
inside D4Z4, rather than on its vicinity, 
could be an initial trigger for FSHD. 
Simultaneously, we worked on developing 
a cell-based system where we could study 
the mechanisms of DUX4 and screen for 
its inhibitors, and on creating a FSHD 
animal model, a DUX4 inducible mouse. 
We developed an in vitro system which 
allowed controlled DUX4 induction in 
myoblasts. By using it we showed that 
DUX4 can provoke FSHD-related cellular 
changes. When expressed at high levels, 
DUX4 is ubiquitously toxic for most of 
the cell types including muscle progenitor 
cells and it also increases cell susceptibility 
to oxidative stress by mis-regulating 
genes involved with buffering the redox 
system in the cells. At low levels DUX4 
interferes with myogenic regulatory factors 
MyoD and Myf5 and it impairs myogenic 
differentiation.
 Support for the prediction that DUX4 
is involved in the disease came from 
the great effort from several groups that 
identified DUX4 at RNA and protein levels 
exclusively in the myoblast and muscle 
biopsy samples from FSHD patients 3456. 
The recent publication described the 
crucial mutation in β-satellite sequence 
on 4q161 haplotype that provides 
stable DUX4 polyadenylation signaling 
reveals DUX4 as a key component in the 
pathogenesis of FSHD7. Thus, we have the 
gene (DUX4), we know something of its 
downstream targets (myogenic regulators, 
redox buffering system, caspases, p53, 
pitx1) and we have a system in which 
we can screen for different therapeutic 
strategies (our DUX4 inducible cell lines). 
 Designing a drug specific to target 
the cause of the disease is one of the 
best approaches to control or cure it. 
To develop a drug means to identify a 
compound with the ability to specifically 
block or regulate the pathological process 
while remaining safe for the rest of the 
organism. In order to find a specific drug 
to FSHD, I formed a collaborative initiative 
with Dr. Kyba and a multidisciplinary 
group consisting of molecular biologists, 
chemists and pharmacists from the 
University of Goce Delcev, the University 
of Minnesota and the UTSW Medical 
Center. The members of this group are 
fortunate to be independently funded 
from various sources including the FSHD 
Society, MDA and NIH. 
The main strategy is to discover a chemical 
compound which specifically binds to 
DUX4 and inactivates it. This potential 
interaction may cause DUX4 to become 
unstable and easily degradable; it could 
modify DUX4 structure that impairs its 
mobility in the cell or its binding ability 
to the target genes. To identify DUX4 
inhibitors we screened more than 200,000 
different compounds from the chemical 
library at UTSW Medical Center for their 
ability to protect the cells from DUX4 
toxicity. The chemical compounds were 
added on DUX4 induced myoblasts and 
their effect was analyzed 24 hours later. 
If the compounds have rescue ability, 
then the DUX4 expressing myoblast 
will survive. Based on this assay we 
selected 586 compounds (0.3% of the 
library) with significant DUX4 rescue 
effect. Several compounds on the list, 
however, indirectly support cell survival 
by affecting downstream targets of DUX4. 
Chemical and structural analyses of the 
lead compounds followed by additional 
screenings for reverting oxidative 
stress induced cell death revealed that 
the majority (more than 70%) of the 
selected compounds are antioxidants. 
Since the redox system is affected in 
DUX4 expressing cells and in the FSHD 
myoblast, antioxidants would provide a 
beneficial effect to them. Therefore, we 
concluded that antioxidants are beneficial, 
but are not specific inhibitors of DUX4. 
Based on those assays, however, we cannot 
exclude that among the antioxidants 
there are no direct DUX4 inhibitors. To 
choose the most potent inhibitor we are 
conducting additional screenings using 
our 586 lead compounds. Some of the 
screenings are designed to distinguish 
whether the rescue is cell specific. Thus 
we generated DUX4 inducible fibroblast 
and human embryonic stem cell lines. 
If the compounds specifically blocked 
DUX4, then the rescue effect will be 
seen in different cell types as well. Our 
results suggest that more than 60% of the 
compounds with rescue effect in myoblasts 
have the same effect in fibroblast. Another 
screening that we are working on aims 
to analyze the level of alternation of 
DUX4 gene targets in the rescued cells. 
For example, stress related genes such as 
MyoD, Myf5, p21 and caspases are known 
to be mis-regulated by DUX4. If the 
compound inactivates the DUX4 protein, 
then the expression of those downstream 
genes should be unchanged. In the assay 
we isolate RNA from cells that are treated 
by compounds and analyze their gene 
expression profile. The last ongoing 
approach is based on the trafficking of 
DUX4 protein. We are developing an 
assay suitable for a large scale study for 
tracking the mobility and the stability of 
DUX4 prior to interaction with the lead 
compounds. 
 We believe that our strategy involving 
the laborious follow up assay will lead to 
the identification of a direct DUX4 inhibitor 
which will be suitable for development into 
a drug for FSHD.   
 
Work made possible by a FSH Society New 
York Festive Evening of Music research 
fellowship grant
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are you clinically diagnosed with fshd but have tested 
negative with genetic testing?
t
Researchers are very interested in identifying FSHD patients who are clinically diagnosed as 
having FSHD and who have genetically tested negative for the 4q35 FSHD deletion. If you are one 
of these individuals, the FSH Society would like to put you in contact with researchers. Please 
contact Daniel Perez at the Society by sending an e-mail with your address, phone and best way 
to reach you to daniel.perez@fshsociety.org with “non4q35” in the subject line or call 617-658-7811.
FshD1B (FshD2) patients sought by research community DOES tHE SOCiEtY HAvE YOUr 
CUrrENt E-MAil ADDrESS?
If we do not have your current e-mail address 
and if you want to be sure of receiving up-to-
the-minute information from the society as 
news breaks, please send your e-mail address 
to us at info@fshsociety.org. Thank you.
The RENEW Biobank is located at the Center for Human Embryonic Stem Cell 
Research and Education (hESC) within the 
Stanford University Institute for Stem Cell 
Biology and Regenerative Medicine.  The 
Center focuses on four areas of primary 
importance in stem cells research: hu-
man embryology, germ cell development, 
reprogramming cells, and directed differen-
tiation of stem cells to other cell types. By 
using human embryonic stem cells (hESCs) 
and alternative pluripotent cells such as 
induced-pluripotent stem cells (iPSCs) as a 
model, it seeks to understand how pluri-
potent cells generate distinct fates during 
human development. At the same time, it is 
setting the stage to translate these findings 
into novel therapeutics. 
 Research on in vitro fertilization and 
the human embryo prior to implantation 
is necessary if scientists are to understand 
human development and treat a wide range 
of human disorders including infertility. 
Advances in human embryonic stem cell 
(hESC) research may someday lead to 
new treatments for adult diseases such as 
muscular dystrophy, spinal cord injuries or 
Alzheimer’s disease.
 If you are interested in donating IVF 
materials for research, or are a clinician 
who wants to offer your patients disposi-
tion options, please contact:
Angie Morey, Research Manager
The RENEW Biobank
650-721-2259 Telephone 
650-498-4320 Fax 
amorey@gmail.com
Human embryonic stem cell (hESC) and 
induced-pluripotent stem cell (iPSC) 
tissue donation for research
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October 1, 2011
Third Annual Walk ‘n’ Roll for Fsh Muscular 
Dystrophy
harwich Bike Trail
harwich community center – 100 Oak street
harwich, Massachusetts  
October 9, 2011
second Annual southern california celebrity 
Walk ‘n’ Roll for Fsh Muscular Dystrophy
October 9, 2011
heritage Park
14301 Yale Avenue
Irvine, california 92604
This year we have taken the event to new 
heights. celebrities will accompany us around 
the lovely park lagoon and mingle with guests 
who have purchased the VIP Lunch sponsored 
by Dave & Buster’s, Irvine. There will be music, 
a silent auction, raffles, prizes and more.
help Raise Funds to “unlock the code”
Two events to Benefit the Fsh society
To register, sign-up or support the events please 
go to the home page of www.fshsociety.org 
and click on ‘Fundraisers’ tab at right. even if 
you cannot attend in person, please consider 
making a contribution to support FshD 
research!
Save the Date!
